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ABSTRACT 
Mechanisms contributing to cancer stem cell expansion and metastasis in skin and 
head and neck squamous cell carcinomas (SCCS and HNSCC) are poorly understood. In 
this study, we show that knockdown of miR-9 decreased SP+ cells in SCCS tumor 
xenografts and decreased invasion. Furthermore, knockdown of miR-9 in mouse SCCS 
xenografts reduced thoracic and lung metastasis. Mice treated with verapamil and 
docetaxel had decreased lung metastasis, suggesting that blocking the ABC transporter 
can work synergistically with chemotherapeutics to decrease metastasis. RNA sequencing 
comparing high miR-9 to lower miR-9 samples revealed several key pathways involved 
in miR-9 mediated metastasis including up regulation of matrix metalloproteinases, and 
cancer stem cell markers, and down regulation of Cxcl cytokines. Contrastingly, we show 
there was no difference in the rate of metastasis to cervical lymph nodes in the miR-9 
overexpressing human HNSCC xenografts. Furthermore, miR-9 had either no change or 
decreased human HNSCC SP+ cell populations in cultured cells and tumor xenografts. 
MiR-9 overexpression in human HNSCC increases migration and invasion of these cells, 
but has no effect on SP+ cancer stem cells or the metastatic potential of these cells. 
Additionally, the contribution of the tumor microenvironment has been shown to 
influence tumor metastasis and progression. In the present study, we generated mouse 
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fibroblasts with a fibroblast-specific TGFβRII deletion (ΔβRII) driven by the collagen 
type-1 alpha 2 promoter or the fibroblast specific protein-1 (FSP1) promoter. We found 
that conditioned media from FSP1.ΔβRII but not Col1a2.ΔβRII fibroblasts increased the 
migration and invasion of HNSCC cell lines. Co-culture of Col1a2.ΔβRII fibroblasts and 
HNSCC tumor cells caused no change in colony formation in soft agar assays. Orthotopic 
xenografts of HNSCC cells co-transplanted with Col1a2.ΔβRII fibroblasts showed no 
difference in growth or cervical lymph node metastasis. Furthermore, chemically-induced 
carcinogenesis was not altered in Col1a2.ΔβRII mice. Our data suggests subpopulations 
of fibroblasts that differentially regulate tumor growth and invasion exist in the HNSCC 
microenvironment. 
 
The form and content of this abstract are approved.  I recommend its publication. 
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Squamous Cell Carcinoma 
 
Squamous cell carcinomas (SCC) are cancers that originate in epithelial tissues 
found throughout the body, including the skin, digestive tract, lung, urinary bladder, and 
cervix, among other sites. Despite arising from a similar cell type, epithelial cells, SCC 
from diverse anatomical locations have different mechanisms of pathogenesis, symptoms, 
treatments, and prognoses, in part due to differences in the microenvironment and 
environmental exposure of that particular niche. This dissertation will focus on SCC 
arising primarily from the head and neck region, as well as the skin. 
 
Squamous Cell Carcinoma of the Head and Neck  
 
Head and neck cancer (HNC) originates in the tissues of the oral cavity, 
nasopharynx, pharynx, oropharynx, larynx, and salivary glands. Squamous cell 
carcinoma (SCC) is the most common cancer type in these mucosal tissues, accounting 
for 90% of head and neck cancers. Head and neck squamous cell carcinoma (HNSCC) is 
the 6
th
 most common malignancy in the world, and continues to have a low 5-year 
survival rate of approximately 50% [1]. In addition to the low survival rate, patients often 
report a decline in quality of life after surgery or radiochemotherapy due to disfigurement 
and dysfunction of critical oral structures. Local spread to cervical lymph nodes is 
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common in patients, as is local reoccurrence and the emergence of a secondary primary 
cancer of the lungs, head and neck, or esophagus [2]. Additionally, in more advanced 
cases of HNSCC, 4-27% of patients will have distant metastasis to the lung (66%), bone 
(22%) or liver (10%), with a very poor prognosis [3].  
Tobacco exposure is an important risk factor for developing HNSCC and is a 
contributing source of mutations in approximately 80-90% of cases [4]. Smokers are up 
to 10 times more likely to develop HNSCC than non-smokers [5]. In addition to tobacco 
use, excessive alcohol consumption is an independent risk factor for HNSCC. Tobacco 
use and alcohol consumption lead to a synergistic increase in the risk of developing 
HNSCC by almost 13-fold [6]. Increased public awareness of tobacco product health 
hazards has led to a decrease in both tobacco use and associated HNSCC in developed 
countries; however, tobacco related HNSCC cases are still a predominant concern in 
many areas worldwide [7]. 
In more recent years, another major risk factor for HNSCC in individuals who are 
non-tobacco and non-alcohol users was identified – human papilloma virus (HPV) 
infection. The increase in HPV-associated HNSCC is attributed to changes in sexual 
behavior. HPV infection preferentially gives rise to oropharyngeal squamous cell 
carcinoma (OPSCC), specifically in the lingual and palatine tonsils [8]. Men have a 
higher incidence of HPV-associated HNSCC than women, possibly due to the increase 
HPV prevalence in cervical as compared to penile tissue [8]. 
In addition to the socially modifiable risk factors described, there are also a 
number of genetically inherited cancer-causing syndromes that can increase an 
individual’s susceptibility to HNSCC. These include xeroderma pigmentosum, ataxia 
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telangiectasia, Bloom syndrome, and fanconi anemia [9]. All of these diseases have 
defective DNA repair mechanisms, implying that DNA instability is an important 
component to HNSCC carcinogenesis. 
One of the hallmarks of cancer is excessive proliferation, which typically arises 
from a combination of genetic mutations and epigenetic alterations resulting in decreased 
apoptosis, increased proliferation, de-differentiation, and angiogenesis. HNSCC 
commonly has alterations in several key signaling pathways that contribute to these 
properties including the epidermal growth factor receptor (EGFR), phosphatidylinositol-
3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR), Janus kinase-signal 
transducer and activator of transcription (JAK-STAT), and transforming growth factor 
beta (TGFβ) pathways [10-16]. HNSCC tumors frequently have alterations in multiple 
signaling cascades in addition to the natural cross-talk between pathways, which 
contributes to the pathogenesis and progression of disease.  
 
Squamous Cell Carcinoma of the Skin  
 
Squamous cell carcinoma of the skin (SCCS) is the second most common human 
cancer, with over 250,000 new cases diagnosed annually in the USA [17]. Over 82% of 
SCCS arise from within precancerous lesions known as actinic keratosis (AK), and up to 
1% of AK progress to SCCS annually [18]. In general, SCCS identified and treated early 
have very good prognosis; however, invasive SCCS or those in immunosuppressed 
transplant recipients can metastasize to local lymph nodes or distant organs such as the 
lungs (21%), bones (18%), central nervous system (6%), or liver  (4%) [19]. In these 
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cases, the 5-year survival is poor, often below 50%. Criteria associated with local or 
distant metastasis include increased vertical thickness of the primary tumor, specific 
tumor locations such as ear, desmoplasia histology, and immunosuppression [20].  
Chronic UV exposure in sunlight and immunosuppression are associated with 
increased risk of developing SCCS.  In more recent years, the use of indoor tanning beds 
has been associated with a 15% increase risk in developing SCCS, as well as an increased 
risk of developing other skin cancers [21]. The use of indoor tanning, as well as increases 
in overall outdoor activity may account for the recent increase in SCCS rates, especially 
among women [22]. 
UVB exposure leads to formation of pyrimidine dimers that must be excised and 
repaired during DNA replication, opening the door for mutations [23]. One common gene 
that is inactivated by UVB signature mutations is p53 [23-25]. Additional common 
mutations are found in the EGFR pathway, overexpression or mutation of Ras, and 
mutations in the TGFβ pathway [26-28]. Epidermal stem cells residing in the hair follicle 
bulge or basal layer of the interfollicular epidermis are thought to be the originating cells 
of SCCS [29].  
 
TGFβ Signaling Pathway 
 
In many cancers, including HNSCC and SCCS, the TGFβ pathway has been 
shown to contribute to tumorigenesis by causing increased EMT, angiogenesis, 
metastasis, and CSC populations. During carcinogenesis, TGFβ signaling has a dual role; 
in normal tissues and early tumorigenesis, TGFβ acts as a tumor suppressor that produces 
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growth inhibition and promotes apoptosis [30]. However, as tumors become more 
advanced, mutations in the TGFβ pathway often lead to overexpression of the TGFβ 
ligand in addition to decreased tumor cell response to the ligand’s suppressive effects. 
Overexpression of TGFβ also induces EMT in tumor cells, resulting in increased invasion 
and metastasis [31]. Furthermore, excessive TGFβ ligand in the tumor microenvironment 
causes other tumor promoting changes, including suppressed immune surveillance and 
increased angiogenesis. 
TGFβ was first described in 1982 as an important mediator of the neoplastic 
transformation process, acting synergistically with TGFα or epithelial growth factor 
(EGF) to promote colony formation of normal rat kidney (NRK) cells in soft agar colony 
growth assays [32]. It was later shown that TGFβ pretreatment of mammary 
adenocarcinoma cells caused increased lung metastasis in a tail-vein injection rat model, 
likely through increasing the breakdown of the extra-cellular matrix (ECM) [33]. A few 
years later, TGFβ was found to induce EMT in normal and transformed mammary cells 
through a process requiring TGFβ receptor I kinase activity [34]. These studies highlight 
the importance of understanding the complex role of TGFβ signaling in tumor 
progression and metastasis. 
In the canonical signaling pathway, TGFβ ligand binds to a heterotetrameric 
receptor complex, consisting of serine/threonine kinases, TGFβ receptors I and II 
(TGFβRI and TGFβRII respectively). Ligand binding causes a conformational shift 
allowing the constitutively active TGFβRII to phosphorylate and activate TGFβRI [35-
38]. Activated TGFβRI phosphorylates the primary downstream signaling molecules in 
the TGFβ pathway, Smad2 and Smad3. Once phosphorylated, Smad2 and Smad3 can 
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bind the common pathway mediator, Smad4, and translocate into the nucleus where they 
interact with other co-activators and co-repressors to regulate gene transcription of 
growth inhibitors, apoptotic regulators, cellular adhesion molecules, and many other 
factors. One of the genes induced by TGFβ ligand binding is the inhibitory Smad7, which 




Figure 1.1  The TGFβ Signaling Pathway.  
Binding of TGFβ ligand to the TGFβRI and TGFβRII causes a conformational shift, 
allowing TGFβRII to phosphorylate TGFβRI. This receptor complex activates Smad2/3 
by phosphorylation, which is inhibited by Smad7. Once activated, Smad2/3 bind with the 
common Smad4 and translocate into the nucleus. The Smad complex binds to promoters 





The Smad pathway is the predominant mechanism through which TGFβ acts to 
modify gene transcription; however, there are other non-canonical signaling pathways 
activated by TGFβ, including MAP kinase, Rho-GTPase, and PI3 kinase/AKT signaling 
pathways. Activation of these pathways can contribute to EMT and stem cell 
characteristics.  
In HNC, alterations in TGFβ pathway regulation can occur through numerous 
mechanisms. Down regulation of TGFβRI and TGFβRII (53.8% and 28.8% respectively) 
is seen in head and neck squamous cell carcinoma (HNSCC) patient samples and 
correlates with increased invasion depth, lymph node metastasis, and a poor prognosis 
[10, 11].  
In addition to down regulation of the receptors, it is also common for tumors to 
have altered Smad signaling. Smad4 is frequently down regulated (86%) as indicated by 
qRT-PCR of HNSCC patient samples [12]. Smad4 loss was found to be a tumor initiating 
and promoting event leading to genomic instability and inflammation. Additionally, 
Smad4 loss correlated with increased invasion, lymph node metastasis, and a worse 
clinical prognosis [13, 14].  Loss of Smad2 is seen in approximately 15-40% of HNSCCs, 
and is correlated with increased local and distant metastasis, as well as disease 
reoccurrence [15, 39].  It was found that pSmad2/3 loss, seen in 8.5% of patient samples, 
correlated with better outcomes than patients with active pSmad2/3 [40]. Unlike Smad2 
and Smad4, Smad3 is typically preserved in HNSCC, and based on skin carcinogenesis 
studies in Smad3 germ line knockout mice, may have a tumor promoting role related to 
altered TGFβ signaling in immune cells [41, 42].  
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Part of the mechanism involved in deregulation of the TGFβ pathway and loss of 
growth inhibition is overexpression of the TGFβ1 ligand, which is seen in 36-43% of 
HNC patient samples [11, 14]. TGFβ1 ligand overexpression can feedback in an 
autocrine fashion to induce EMT in tumor cells, while also acting as a paracrine factor to 
activate fibroblasts in the surrounding stroma, contribute to angiogenesis, and cause 




Epithelial-to-mesenchymal transition (EMT) is a normal physiological process 
critical for proper embryogenesis and development, as well as adult wound healing [31, 
45]. It allows cells to alter their morphology and polarity, breakdown cellular adhesion 
complexes, and digest extra-cellular matrix, ultimately resulting in cell migration to other 
locations in the body where they participate in reconstruction and repair [46]. EMT has 
naturally been one of the major focuses of cancer research in the past 20 years, in part 
because of the clear association it has with disease progression and metastasis.  One of 
the key identifying markers of EMT is decreased epithelia cadherin (E-cadherin) 
expression, which results in reduction of adherens junctions, modification of Rho GTPase 
function, and release of β-catenin from the adherens junction complex. In addition to 
decreased E-cadherin expression, increased vimentin expression, loss of polarity 
complexes including Crumbs protein homolog-3 (CRB3) and Lethal giant larvae-2 
(LGL2), changes in cytoskeletal elements, and the ability to produce matrix 
metalloproteinases (MMPs) are associated with EMT. Moreover, EMT in cancer is 
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influenced by many contributing cytokines, transcription factors, and cellular adhesion 
proteins.  
 
EMT in HNC  
 
Numerous key components of EMT in HNC have been identified (Figure 1.2). 
Nijkamp et al showed low expression of the epithelial adhesion molecule E-cadherin and 
high expression of the mesenchymal intermediate filament vimentin were significantly 
associated with increased distant metastatic potential in HNSCC patients as compared to 
the remaining patients in the study (100% vs. 44% respectively) [47].  Tropomyosin-
related kinase B (TrkB) and transcription factor Slug (Snail2) overexpression have both 
been shown to cause down regulation of E-cadherin and increased migration in HNC [48, 
49]. Furthermore, Slug has been shown to cause up regulation of N-cadherin, a neuronal 
adhesion molecule normally not expressed in epithelial cells, and decreased expression of 
desmosomal proteins, including desmoplakin, in HNC [48]. In addition to Slug, another 
E-cadherin transcriptional repression factor, Zinc finger E-box-binding homeobox 1 
(ZEB1), is associated with decreased E-cadherin and EMT in HNC [50]. 
Growth factors and growth factor receptors play a critical role in EMT induction. 
Studies have found 80-90% of HNSCC had overexpression of epidermal growth factor 
receptor (EGFR), which induced EMT, increased MMP-9 production, and decreased E-
cadherin expression [51]. These changes were associated with increased cell motility, 





Figure 1.2  Characteristics of EMT.  
Normal epithelial cells express epithelial markers and have numerous cell-cell 
connections including tight junctions, adherens junctions, and desmosomes. Additionally, 
these cells have cobblestone morphology and defined polarity. Overexpression of 
numerous growth and transcription factors contributes to EMT. After undergoing EMT, 
cells no longer express many of the epithelial factors, and instead express numerous 
mesenchymal markers. These cells also express proteases that breakdown the basement 
membrane, allowing them to invade. After EMT, cells have a spindle-like morphology 
and are more motile. 
 
Bone morphogenetic proteins (BMPs) have been associated with EMT and 
metastasis in HNSCC [54]. Immunohistochemistry (IHC) showed increased BMP-4 and 
p-Smad1, a downstream transcription factor in the BMP pathway, in samples from 
HNSCC patients with lymph node metastasis as compared to samples from patients 
without lymph node metastasis [55, 56].  In vitro studies show knockdown of Smad1 
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suppressed EMT induction by BMP4 and caused decreased invasion and migration.  In 
addition to the above described pathways, both the canonical and non-canonical TGFβ 




Regulation of EMT by TGFβ Signaling in HNC  
 
Activation of the TGFβ pathway in HNC causes tumor cells to adopt a 
mesenchymal phenotype, which is represented by loss of E-cadherin, up regulation of 
mesenchymal markers, a spindle-like morphology, and increased motility. Activation of 
multiple cellular pathways is involved in this process. 
TGFβ1 was initially shown to induce EMT in normal and transformed mammary 
epithelial cells, specifically through a TGFβRI-mediated mechanism [34]. It was soon 
found that TGFβ1 can induce EMT in virtually all epithelial cell types. More recently, 
Han et al found that deletion of TGFβRII decreased TGFβ1 induced EMT [57], 
suggesting TGFβ1 induction of EMT through a receptor-dependent mechanism. In 
HNSCC, TGFβ1 overexpression has been shown to contribute to increased MMP-9 and 
breakdown of the extracellular matrix through regulation of myosin-light chain kinase, 
leading to increased ECM breakdown and invasion [58, 59]. 
Many TGFβ1 ligand induced genes are regulated through the Smad pathway, 
which is a key component of TGFβ mediated EMT. Petersen et al showed knockdown of 
Smad3 caused increased latency and delayed bone metastasis in a breast cancer model. 
However, in this same model, Smad2 knockdown caused more aggressive metastasis than 
seen in the control, suggesting that Smad2 and Smad 3 have divergent roles [60]. 
12 
 
Additionally, Hoot et al found that Smad2 ablation in mouse keratinocytes increased 
EMT and caused more poorly differentiated histology in skin SCC [61]. In contrast, the 
spontaneous HNSCC tumors that arise from knockout of the common Smad4 resulted in 
tumors with increased genomic instability and inflammation; however, the tumors were 
well-differentiated and did not show evidence of EMT as seen in Smad2 knockout tumors 
[12]. Further analyses revealed that Smad2 loss-associated EMT required increased Snail 
expression mediated by Smad3 and Smad4 [61]. These data suggest that Smads have 
distinct roles in EMT and tumor progression. 
Smads can interact with other transcription factors to regulate gene expression 
and EMT. One important example of this is Smad interaction with ZEB proteins, 
including ZEB1 and ZEB2/SIP1. The ZEB transcription factors have a Smad binding 
domain that can directly interact with Smads [62, 63]. However, Shirakihara et al showed 
that E-cadherin repression by ZEB2 is independent of Smad binding. Furthermore, ZEB1 
and ZEB2 were necessary for TGFβ-mediated EMT, and that induction of these factors 
was likely regulated through transcriptional activation by Smads [64]. 
Janda et al showed the TGFβ and Ras signaling pathways work synergistically to 
induce EMT. They used Ras-transformed or non-transformed mammary epithelial cells in 
combination with Ras-pathway inhibitors to show that the Raf/MAPK pathway was 
required for sustained TGFβ1-mediated EMT, tumorigenesis, and metastasis [65]. This 
pathway is important in HNCs as well. H-Ras mutation occurs in 4-5% of human HNCs 
[66, 67]. Further, Lu et al found that 63% of HNSCC patient samples had Ras mutations 




Non-Canonical TGFβ Signaling in EMT  
 
While the Smad pathway influences TGFβ induced EMT, there are several other 
important mechanisms driving this tumor-promoting change independent of Smad 
activation. TGFβRII can phosphorylate the polarity protein PAR6, which causes local 
degradation of the RhoA small GTPase and disassembly of intercellular tight junctions in 
mammalian cells [69, 70]. Additionally, TGFβRI binds to the ubiquitin ligase TRAF6, 
which mediates activation of several MAP kinase kinases including TAK1, MAPKK3/6, 
and the Jun/p38 pathway [71-73].  However, Yu et al showed that mammary tumor cells 
need active Smad signaling in addition to p38 pathway activation to achieve complete 
EMT [71]. In fact, elevated p38 levels have been seen in patient HNSCC samples [74]. 
This suggests that while non-canonical mechanisms of the TGFβ pathway contribute to 
EMT, Smad signaling likely works synergistically with these additional pathways to 
maintain a complete EMT phenotype. 
 
Mechanisms of Metastasis 
 
In cancer, changes in the tumor cells representing a more motile, elongated cell 
with a more mesenchymal phenotype is one proposed step towards metastasis; however, 
before cells can metastasize, numerous other complex events need to be orchestrated 
including breakdown and reorganization of the extracellular matrix fibers, intravasation 
into systemic blood flow, priming of the metastatic location, extravasation to the 





Figure 1.3  Mechanisms of Metastasis.  
(1) Primary tumor cells proliferate, and undergo changes that allow them to secrete 
factors, such as MMPs, that break down the ECM and disrupt the basement membrane. 
(2) Tumor cells that have undergone EMT migrate and invade through the basement 
membrane and remodeled epithelial cells by using filopodia and invadopodia. (3) An 
alternative mode of cell migration is collective cell migration. (4) Once tumor cells have 
migrated to the blood vessel, cells slip between the endothelial cells to enter circulation, a 
process known as intravasation. (5) Before tumor cells can establish at the new metastatic 
site, the location is primed to form a metastatic niche. (6) Circulating tumor cells exit the 
blood vessels near the metastatic niche by extravasation. (7) Tumor cells migrate to the 
metastatic site, and establish a colony in part by reversing EMT through MET, as well as 
establishing new angiogenesis.  
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EMT is one mechanism proposed to be involved in invasion and metastasis; 
however, another theory involves a process known as collective cell migration. Collective 
cell migration is a coordinated migration of a group of cells through a cooperative effort, 
and has been observed for many years in embryogenesis and wound healing. More 
recently, studies have shown that collective cell migration can be involved in regulating 
cancer metastasis. In this process, cell adhesion are maintained and thought to be a 
critical component to collective cell migration. For example, a recent study found that N-
cadherin expression is necessary for collective cell migration of prostate tumor cells in a 
3D culture model [75]. Other signaling pathways have also been indicated in collective 
cell invasion. In fact, a study showed that involvement of TGFβ pathway crosstalk 
between tumor cells and tumor stroma contributes to collective cell migration and 
increased metastasis through an increase in extravasation [76]. 
An important part of metastasis involves the ability of the tumor cells to rearrange 
actin filaments into filopodia and invadopodia to facilitated tumor cell movement and 
breakdown of the ECM  [77]. One protein, fascin, has been shown to regulate actin 
remodeling in filopodia formation in tumors and contribute to a poor prognosis [78-80]. 
Additionally, tumor cells overexpressing podoplanin, a protein that enhances filopodia, 
caused increased tumor invasion  and collective cell migration while cells maintained an 
epithelia phenotype, suggesting that EMT is not necessary for cell invasion and motility 
[81, 82]. However, a study recent study found that there may be more heterogeneity at the 
invasive front of tumors, and the crosstalk between cells that have undergone EMT and 
those that maintain an epithelial phenotype in the tumor nest is important for invasion. 
This study found that Snail expression in EMT cells lead to secretion of Cystein rich 
16 
 
61(Cyr61), an extracellular protein, which activated collective cell migration in SCC 
through a paracrine mechanism [83].  
Breakdown and reorganization of the extra cellular matrix occurs primarily 
through the release of proteases such as MMPs by both the tumor cells as well as tumor-
associated fibroblasts as well as modifying integrin expression patterns (reviewed in [84, 
85]. In part, this can be regulated through specialized filopodia, known as invadopodia, 
which cause focal degradation of the ECM by directing the release of MMPs to the area 
of migration. The presence of invadopodia is correlated with tumor aggressiveness and 
metastasis and studies have shown that invadopodia are associated with a poor prognosis 
in several cancer types including HNSCC and SCC [86, 87]. In addition to breakdown of 
the ECM, invadopodia have been indicated in mediating intravasation as well, in part 
through an N-WASP mediated mechanism [88, 89]. 
Understanding how tumors prepare the metastatic niche is an important emerging 
field of cancer research. Originally, it was thought that tumors migrated to organs that 
either resembled the primary site, or that were rich in growth factors. However, more 
recently work has shown that tumor cells are actively involved in creating a pre-
metastatic microenvironmental niche that creates a hospitable environment for the tumor 
cells. Recruitment of bone marrow derived hematopoietic progenitor cells to the pre-
metastatic site is thought to be a crucial event in preparing the niche for future tumor cell 
colonization [90].  
 In order for circulating tumor cells to colonize a new location, they must first exit 
the blood vessel, a process known as extravasation. The first step in this process is the 
ability of the tumor cell to adhere to the endothelial wall of the blood vessel. There are 
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two proposed mechanism for this. The first is that the tumor cells undergo site-specific 
adhesion at primed sites through a process that is similar to the adhesion of circulating 
and extravasating immune cells. The second theory is that since tumor cells tend to be 
larger than other circulating cells, can form aggregations with platelets, and may migrate 
in a collective fashion, the tumor cells are prone to becoming wedged in the blood 
vessels, creating contact with the endothelial cell wall. Studies have shown that both of 
these processes occur in metastasis [91-93]. While the overall process of extravasation of 
tumor cells is still poorly understood, recent studies have  shown that the majority of 
tumor cells that are capable of extravasating do so by causing increased endothelial wall 
permeability, and transmigrate across the endothelium into the host organ extracellular 
matrix within 24 hours of making contact with the endothelial wall [94].  
 Once cells have entered the extra cellular matrix of the primed metastatic niche, 
they need to become established, recruit blood vessels, and proliferate. Studies have 
shown that an important part of this process is reversal of EMT to undergo mesenchymal-
to-epithelial transition (MET) and establish colonization [95, 96]. Two recent studies 
indicated that MET at the secondary site was necessary for tumor proliferation and was 
achieved through down regulation of key EMT transcription factors, Twist and Prrx1 [97, 
98]. It is clear that the metastatic tumor microenvironment established prior to migration 
of tumor cells is likely involved in this process as well. Bone-marrow derived 
hematopoietic stem cells recruited to prime the metastatic site have been shown to 
activate angiogenesis and tumor cell proliferation through a PDGFR mediated fashion 
[99].  Some of the additional pathways involved in the tumor-stromal crosstalk necessary 
to establishing a successful proliferating tumor colony including hypoxia-inducible 
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factors, BMP pathway, and miR-200 mediated mechanisms  (reviewed in [100, 101]). 
While studies have shed some light on the pathways necessary for successful rooting of 
tumors in the secondary site, more research is needed in this area to fully understand the 
molecular orchestration that allows successful metastasis. 
 
Cancer Stem Cells 
 
In more recent years, researchers have discovered that tumors consist of a very 
heterogeneous cell population; a small subpopulation of these cells, termed cancer stem 
cells (CSCs) or tumor initiating cells, have two key properties--the ability to self-renew, 
and the ability to regenerate the heterogeneity of the parental tumor [102].  CSCs have 
been implicated in tumor progression, metastasis, drug resistance, and reoccurrence.  
There are two predominant hypotheses on the origin of CSCs. CSCs can arise 
from the transformation of normal adult tissue stem cells that have accumulated 
numerous mutations, or they can develop from progenitor cells that have acquired 
mutations endowing the tumor cell with self-renewing capabilities [103].  Recently, Mani 
et al identified another key feature of CSC populations, EMT [104]. They found that 
induction of EMT by TGFβ treatment in mammary epithelial cells increased expression 
of CSC markers, and transformed mammary epithelial cells that had undergone EMT 
were more able to form colonies in soft agar and tumors in mice as compared to 
transformed cells that did not undergo EMT induction. Additionally, they saw that CSCs 
isolated from mammary carcinomas expressed EMT markers, and EMT transcription 
factors including Snail and Twist were up regulated [104].  In SCC, Biddle et al showed 
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there are two distinct populations of CSC, one that is migratory with an EMT phenotype, 
and one that is proliferative with an epithelial phenotype [105].  
 
ABC Transporters as Markers of CSCs   
 
ABC transporters were first identified as stem cell markers by their presence on 
CD34+ hematopoietic stem cells [106]. It was discovered that these transporters efflux 
Hoechst 33342 dye, enabling stem cells that express ABC transporter to be isolated by 
flow cytometry [107]. Further studies showed that this Hoechst dye effluxing side 
population of cells (SP) could be used to isolate stem cells in numerous tissues, including 
tumors [108-110].  
The ATP binding cassette (ABC) transporter superfamily consists of 
approximately 48 genes that are normally involved in the movement of a variety of 
substrates, including lipids and metabolic products, across cellular membranes [111, 
112]. However, these transporters can be up regulated in cancer, contributing to 
chemoresistance [111]. Animal studies have shown that tumors deficient in ABC 
transporters are more susceptible to chemotherapy [113, 114]. In addition to the ability of 
the ABC transporters to efflux chemotherapeutic drugs, they influence CSC survival by 
decreasing apoptosis more directly. Studies have shown that overexpression of certain 
ABC transporters delay the onset of and protect cells from caspase-dependent apoptosis 
[115-117]. 
Of the ABC transporter genes, ABCB1, corresponding with the multi-drug 
resistant-1 (MDR1) protein, is well chacterized for its role in tumor formation, invasion, 
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metastasis, and chemoresistance in numerous cancers including colorectal, breast, and 
melanoma [118-120]. ABCB1 is up regulated in cancer cells at the transcriptional level in 
part by CD44-mediated mechanisms involving p300 activation of β-catenin and NFκB 
[121, 122]. 
 
CSC in HNC  
 
Prince et al were first to show a CSC population in HNC-CD44+ cells. However, 
large numbers of these cells were necessary to initiate a tumor (>5,000 cells) [123]. 
Another study showed that CD44- cells in HNC also had CSC properties, implying there 
may be numerous CSC populations within a given tumor [124, 125]. Research in recent 
years has focused on markers to identify these populations. Several other putative HNC 
stem cell markers identified include aldehyde dehydrogenase 1 (ALDH1), CD34, CD117, 
CD133, and Hoechst side population (SP) [125-129]. 
Yang et al showed that in HNC Twist1 overexpression resulted in up regulation of 
Bmi1, which caused induction of EMT, increased tumor-initiating capabilities, and 
increased expression of CSC markers. Furthermore, high levels of both Twist1 and Bmi1 
were associated with decreased survival in HNC patients [130].  Another study found that 
increased ZEB1/2 co-expression was associated with a poor prognosis and an increase in 
the CD133+ CSC population [131].  These studies suggest that not only are EMT and 
CSC properties associated with each other, but they also can be used as prognostic 




CSC in SCCS  
 
SCCS have specific CSC populations as well. CD133+ cells isolated from 
primary human SCCS showed CSC properties, and were able to recapitulate the 
heterogeneity seen in the original tumor [132]. Geng et al showed that a subpopulation of 
SCCS cells that are CD29high/CD44high are CSCs that have also undergone EMT [133]. 
Studies have also identified that some SCCS have an SP population that has CSC 
properties [134, 135]. 
 
Link between EMT, CSCs, and Metastasis  
 
EMT is often discussed as being linked to metastasis. In fact, there are numerous 
studies in HNC supporting this conclusion [47, 53, 136-138]. However, some recent data 
suggests that EMT and metastasis are not always associated. Han et al found tumors 
containing deleted TGFβRII and TGFβ1 overexpression were still able to metastasize, 
despite maintaining E-cadherin expression, suggesting that alternative non-canonical 
pathways, such as the RhoA/Rac and MAPK, may play important roles [57]. Likewise, 
Lu et al found that mouse models with K-Ras activation and decreased TGFβRII 
expression developed HNSCC with 100% penetrance, 35% of which had lymph node 
metastasis, yet these tumors had not gone through EMT [68]. Similarly, Smad2 deficient 
tumors had increased EMT with decreased metastasis compared to Smad4 deficient 
tumors that had lung metastasis despite relatively decreased EMT [61, 139]. This 
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suggests it is possible EMT and metastasis are not directly linked, and that the TGFβ 
pathway may be a key regulator of both of these processes.  
CSCs may be a better indicator of metastatic potential, although, as described 
previously, there is a clear link between CSCs and EMT. In HNC, CSCs isolated as 
CD44+, ALDH1+, and SP+ all were shown to have increased metastasis as compared to 
non-CSC enriched tumor grafts [126, 127, 140-142]. Similarly, Biddle et al showed that 
between two distinct CSC populations having either epithelial or mesenchymal 
phenotypes, only ALDH1+ cells were able to transition from a mesenchymal to epithelial 
morphology, implying that only ALDH+ cells are able to seed a metastatic site [105]. 
While there appears to be an association between CSCs and metastasis, evidence for a 
clear mechanism linking these two remains elusive. Additional studies clarifying the 
contributions of EMT and CSCs to metastasis and tumor progression in HNC are 
necessary to provide additional insight into novel treatment approaches. 
 
MicroRNAs in Cancer 
 
The role of miRs in cancer has received much attention in recent years. MiRs are 
small (18-24 nucleotide), non-coding RNAs that regulate post-transcriptional gene 
expression. They are transcribed as precursors that need to be processed by the DROSHA 
complex and exported to the cytoplasm by Exportin5 before they can interact with target 
mRNAs [143, 144]. MiRs regulate gene expression by binding to the 3’ UTRs of target 
mRNAs, causing either degradation of the mRNA by the RNA-induced silencing 
complex (RISC) if it is an exact match, or translational repression in the case of an 
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imperfect match [145]. In the past several years, researchers have begun to uncover the 
diverse role that miRs play in almost every biological process, including cancer, where 
they can have either oncogenic or tumor suppressive properties [146, 147].  
 
MicroRNA contributions to EMT and CSCs in HNC  
 
Some miRs have been implicated in EMT (Figure 1.4). Park et al found that in 
ovarian cancer, the miR-200 family targets ZEB1 and ZEB2; hence, decreased expression 
of miR-200 resulted in ZEB-mediated E-cadherin repression, vimentin up regulation, and 
EMT induction [148]. In HNSCC, Lo et al found decreased expression of miR-200c in 
regional lymph node metastasis, as well as increased Bmi1 expression. They showed 
Bmi1 was a target of miR-200c, and that overexpression of miR-200c or knockdown of 
Bmi1 inhibited CSC properties and caused decreased lung metastasis. Furthermore, they 
showed that overexpression of miR-200c decreased Snail, ZEB1, and N-cadherin 
expression [149]. It has been shown that in lung cancer, expression of the miR-200 
family can be repressed by ZEB1 and ZEB2, suggesting a complex negative feedback 
loop [150]. TGFβ treatment induced EMT that was accompanied by decreases in the 
miR-200 family, elevated ZEB1/2 mRNA, and decreased E-cadherin. In fact, Gregory et 
al found prolonged treatment with TGFβ caused DNA methylation of the miR-200 loci 
that correlated with decreased miR-200 levels [151, 152]. TGFβ regulation of both ZEB1 





Figure 1.4  TGFβ Regulation of MiRs Involved in EMT.  
TGFβ causes methylation and inhibition of the miR-200 family. The miR-200 family 
targets several transcription factors that are involved in regulation of EMT and CSCs. 
TGFβ also decreases mature Let-7. Let-7 targets transcription factors involved in EMT. 
MiR-155 is up regulated with TGFβ activation, although the mechanism is not clear. 
MiR-155 targets additional EMT regulators. 
 
 
Reduced expression of miR Let-7 has been associated with a poor prognosis in 
HNSCC [154]. Let-7 targets HMGA2, which is involved in regulating TGFβ induced 
Twist and Snail expression [155, 156]. Therefore, decreased Let-7 would alleviate 
inhibition on these two major regulators of EMT. Additionally, in pancreatic cancer, 
TGFβ1 treatment can repress mature Let-7 but not the precursor of Let-7 through MMP-
14 [157], implying that the TGFβ pathway can impact miR expression at multiple levels. 
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Several studies have shown that miR-155 is increased in HNC. One possible 
mechanism of how this overexpression contributes to oncogenesis is through targeting 
the tumor suppressor and epithelial marker APC [158].  In breast cancer, miR-155 was 
shown to contribute to TGFβ mediated EMT through targeting RhoA [159].  
 
MicroRNAs in SCCS  
 
There are numerous miRs that have been implicated in SCCS. Down regulation of 
several key miRs including miR-361-5p, miR-124, miR-214, and miR-125b allow 
overexpression of tumor-promoting proteins including VEGFA, ERK1, ERK2, and 
MMP13 respectively [160-162].  MiR-21 overexpression decreases GRHL3, which 
results in down regulation of PTEN, activation of the PI3K/AKT/mTOR pathway, and 




MiR-9 was first discovered as a regulator of neuronal embryogenesis, 
proliferation, migration, and differentiation; it is expressed predominantly in neuronal 
tissues [164-166]. MiR-9 is highly expressed in neuronal progenitor cells, and influences 
both the proliferation and migration ability of these cells [167]. It is also thought that 
miR-9 can suppress apoptosis in neuronal progenitor cells through a p53 mediated 
mechanism [168]. Humans have three copies of miR-9, which are located on 
chromosomes 1, 5 and 15.Aberrant levels of miR-9 are seen in many kinds of cancer, 
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suggesting that deregulation of this miR is important in malignant pathways. However, 
miR-9 has a controversial role in cancer progression; in some cancers it seems to act as a 
tumor promoter, while in others, as a tumor suppressor. This suggests that miR-9 may 
have tissue specific targets with opposing effects on proliferation and metastasis. For 
example, miR-9 is down regulated in ovarian cancer, neuroblastomas, and 
meduloblastomas, where it is thought to contribute to proliferation by alleviating 
inhibition of cell growth regulators [169-171]. In ovarian cancer, miR-9 overexpression 
causes decreased proliferation by down regulating NFκB1 [172]. Conversely, miR-9 is 
overexpressed in Hodgkin’s lymphoma, primary brain tumors, and some gastric cancers, 
where it contributes to the proliferation of these tumors [173-176]. MiR-9 induces EMT 
and angiogenesis in epithelial and breast cancer cells through down regulation of E-
cadherin [177]. Furthermore, secretion of miR-9 by tumor cells causes endothelial cell 
migration and tumor angiogenesis through activation of the JAK/STAT pathway [178]. 
However, given the tissue-specific targets of miR-9, it is not known how this miR will 
influence HNSCC and SCCS.  
This dissertation work will use miR-9 overexpressing or knockout cell lines 
generated from K15.Kras
G12D
.Smad4-/- SCCS tumors or established HNSCC cell lines to 
further understand the role of miR-9 in HNSCC and SCCS cancer stem cell populations 
and metastasis. We hypothesize that miR-9 will increase tumor invasion, metastasis, 
and CSC populations in SCCS and HNSCC through E-cadherin based mechanisms. 
The following aims were used to direct the work of this project: 
Aim1: Examine the influence of miR-9 on SCCS and HNSCC tumor 
proliferation, migration, invasion, and metastasis. 
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Aim2: Determine the effect of miR-9 on CSC populations in SCCS and HNSCC 
tumors. 
The work of this dissertation shows that overexpression of microRNA-9 (miR-9) 
contributes to an increased percent of SP+ cells in mouse SCC tumor xenografts, and 
caused increased invasion. Likewise, knockdown of miR-9 decreased the percent of SP+ 
cells in SCC tumor xenografts and decreased invasion. Furthermore, knockdown of miR-
9 in mouse SCC xenografts reduced both thoracic and lung metastasis as compared to the 
GFP control. We identified α-catenin as a predominant miR-9 target, and increased miR-
9 in human SCC metastases correlated with α-catenin loss but not E-cadherin loss. To 
determine if blocking the ATP binding cassette (ABC) transporters, which are associated 
with SP+ cells, could decrease lung metastasis, mice with SCC xenografts were treated 
with verapamil (an ABC transporter antagonist) or verapamil in combination with a 
common chemotherapeutic, docetaxel. Mice treated with both verapamil and docetaxel 
had decreased lung metastasis, suggesting that blocking the ABC transporter can work 
synergistically with chemotherapeutics to decrease metastasis in SCC. Our data reveal 
that miR-9 overexpressing SP+ cancer stem cells that have increased metastatic potential. 
 
Role of TGFβ in Cancer-Associated Fibroblasts of the Tumor Microenvironment 
 
Tumor cells are not isolated entities; they depend on a network of surrounding 
cells - fibroblasts, endothelial cells, and immune cells – to proliferate and thrive. The 
cells integrated into and surrounding the tumor that support tumorigenesis create what is 
known as the tumor microenvironment. Within the tumor microenvironment is a complex 
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milieu of signaling molecules and growth factors that participate in a bi-directional 
communication between the tumor cells and the tumor stroma. 
TGFβ is a major player in modulating the tumor stroma, recruiting immune cells, 
and shifting the response of these cells towards a tumor-promoting, pro-metastatic state. 
TGFβ is involved in activating normal, quiescent fibroblast into activated fibroblast in 
wound healing as well as in the tumor microenvironment [179-181]. Cancer-associated 
fibroblasts (CAF) secrete many growth factors and cytokines that are tumor promoting 
including HGF, EGF, IGF, IGFBPs, FGF, and TGFβ (reviewed in [182]). CAFs 
contribute to angiogenesis by their location at the leading edge of the tumor as well as 
VEGF and FGF-2 secretion [183-185].  
Fibroblasts have not only been shown to be important in the progression of 
cancer, but also in tumor initiation. CAFs isolated from prostate, lung, and mammary 
cancers are able to transform non-malignant epithelial cells [186-188]. Furthermore, Wnt 
overexpression in fibroblasts was sufficient to transform mammary epithelial cells [189].  
Mouse models with TGFβRII deletion targeted to fibroblasts using fibroblast specific 
protein (FSP) developed carcinoma of the forestomach and prostate, but did not develop 
cancers in other tissue types [190]. Conversely, normal fibroblasts are able to convert 
malignant prostate and skin epithelia to benign lesions [191, 192]. These data suggest that 
CAFs can play a role in tumor initiation, but there is likely a tissue-dependent mechanism 
involved.  
TGFβ-1 ligand and HGF, among other factors, secreted by CAFs are involved in 
tumor cell EMT, invasion, and metastasis [193, 194]. Additionally, CAFs in the invasive 
front of tumors contribute to invasion through matrix remodeling mediated in part by 
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caveolin-1 [184, 195]. CAFs are a necessary component of the metastatic site as well. 
One study showed that periostin production by fibroblasts at the site of micrometastases 
was critical for colonization by tumor cells, as well as maintenance of CSC properties 
[196]. One study even showed that CAFs are transferred from the primary tumor to the 
metastatic niche [197]. These studies highlight the importance of CAFs in tumor 
progression and suggest targets in the tumor microenvironment alone or in addition to 
targeting tumor cells as interesting therapeutic directions to investigate. 
CAFs ability to accumulate genetic alterations similar to their tumor counterpart 
is a controversial topic. Some evidence suggests that mutations in CAFs might play a 
critical role in cancer progression, while other studies implicate experimental error in 
mistaking EMT tumor cells for CAFs as the basis for these results. For example, one 
study examining clonal somatic genetic alterations in breast cancer found no evidence of 
any abnormalities [198]. However, another study examining mammary CAFs found that 
these cells had decreased p53/p21 and high survivin levels [199]. Other studies have 
shown decreased expression or loss of heterozygosity of TGFβRII is present in the 
fibroblast in the tumor microenvironment in HNSCC [200, 201].  
To better understand the contribution of TGFβ signaling in CAFs in HNSCC and 
the role of different fibroblast subpopulations, this dissertation will examine the role of 
disrupted TGFβ signaling in fibroblasts of the HNSCC microenvironment using collagen 
type 2a (Col1a2) or fibroblast specific protein-1 (FSP1) to target conditional TGFβRII 
deletion to a subpopulation of fibroblasts. We hypothesize that TGFβRII deletion in 
oral fibroblasts will create a cancer-promoting tumor microenvironment. Several 
pathways such as growth factor secretion and modification of the extra-cellular 
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matrix may contribute to this response. Investigating the mechanism through which 
this deletion contributes to the tumor microenvironment will shed light on the complex 
tumor-stroma interaction. The following aims were used to direct the work on this 
project:  
Aim1: Determine genes and pathways that are altered in fibroblasts with TGFβRII 
deletion.  
Aim2: Examine the influence of TGFβRII deletion fibroblasts on HNSCC growth, 
invasion and metastases.  
The work of this dissertation shows that conditioned media from FSP1 driven but 
not Col1a2 driven TGFβRII-deleted fibroblasts increased the migration and invasion of 
HNSCC cell lines. Additionally, co-culture of TGFβRII-deleted fibroblasts and HNSCC 
tumor cells caused no change in colony formation in soft agar assays. Orthotopic 
xenografts of HNSCC cells co-transplanted with TGFβRII-deleted fibroblasts showed no 
difference in growth or local lymph node metastasis. Microarray analysis revealed that 
Col1a2 TGFβRII-deleted fibroblasts did not show up regulation of HGF or TGFα, two 
previously identified growth factors secreted by FSP1 TGFβRII-deleted fibroblast. Our 
data suggests that subpopulations of fibroblasts that differentially regulate tumor growth 







MICRORNA-9 REGULATES INVASION, MIGRATION, METASTASIS, AND 





Mechanisms contributing to cancer stem cell expansion and metastasis in skin 
squamous cell carcinomas (SCCS) are still poorly understood. In this study, we show that 
knockdown of miR-9 decreased the percent of SP+ cells in SCCS tumor xenografts and 
decreased invasion. Furthermore, knockdown of miR-9 in mouse SCCS xenografts 
reduced both thoracic and lung metastasis as compared to the GFP control. To determine 
if blocking the ATP binding cassette (ABC) transporters, which are associated with SP+ 
cells, could decrease lung metastasis, mice with SCCS xenografts were treated with 
verapamil (an ABC transporter antagonist) or verapamil in combination with a common 
chemotherapeutic, docetaxel. Mice treated with both verapamil and docetaxel had 
decreased lung metastasis, suggesting that blocking the ABC transporter can work 
synergistically with chemotherapeutics to decrease metastasis in SCCS. RNA sequencing 
comparing high miR-9 to lower miR-9 expressing tumor and cell line samples revealed 
several key pathways that may be involved in miR-9 mediated metastasis including up 
regulation of matrix metalloproteinases, down regulation of Cxcl cytokines, and up 
regulation of cancer stem cell markers. Our data reveal that miR-9 overexpression in 





Squamous cell carcinomas (SCCs) are derived from stratified epithelia present 
within the skin and oral cavity. A subset of aggressive SCCs becomes metastatic, leading 
to metastasis-associated death. The rate of metastasis in skin SCCs ranges from 0.1-10% 
[202], with poorly differentiated tumors and those with greater vertical tumor thickness 
having an increased risk of metastasis [203]. Genetic alterations and intrinsic tumor cell 
properties controlling SCC metastasis are largely unknown. Genetically engineered mice 
provide a powerful tool for dissecting driver mutations contributing to SCC initiation and 
metastasis. To date, very few genetic mutations have been found that can cause 
spontaneous SCC formation and metastasis, particularly metastasis to the lung, which is 
the leading cause of SCC-associated death [204]. Previous unpublished data in our lab 
done by Ruth White shows that targeting Smad4 deletion in combination with Kras
G12D
 
activation, two mutations commonly occurring in human SCCs with a frequency of up to 
84% and 1-12%  respectively [61, 68, 205-207], to K15
+
 hair follicle bulge stem cells 
initiates multi-lineage tumors, including SCCs that are highly metastatic to the lungs. 
Furthermore, these studies showed that microRNA-9 (miR-9) was correlated with SP cell 




 SCCS (Figure 2.1). While there 
appears to be an association between CSCs and metastasis, evidence for a clear 
mechanism linking these two remains elusive. In the current study, we provide evidence 













 mice.  




 SCC, Basaloid SCC 
(BSCC) and SCC lung metastasis. The scale bar in the left panel=100 m for all panels. 
(B) Analysis of the SP size (% of viable cells sorted) in metastatic (n=15) and non-
metastatic (n=9) tumors. Diamonds indicate SP sizes of individual tumors, and bars 
represent averages. *: p= 0.009 compared to SP sizes in non-metastatic SCCs. (C) miR-9 
expression levels correlated to the SP sizes of tumors. Significance was determined by 
calculating the correlation coefficient (R
2










MicroRNA-9 (miR-9) Contributed to SP Expansion and SCCS Metastasis  
 









 tumors with decreased 
levels of miR-9 expression (courtesy of Ruth White). We stably transfected a 
“miRZip
TM
” (System Bioscience) anti-miR (Zip-9), to knock down miR-9, into 
B931cells, a cell line with higher intrinsic miR-9 expression. Since miR-9 was highly 
expressed in aggressive tumors, we examined if altering miR-9 expression affects tumor 
cell growth or metastasis. After confirming changes in miR-9 expression and activity in 
the cell lines after transfection (Figure 2.7), we transplanted 2,500 tumor cells into the 
flanks of athymic nude mice to examine tumor growth and metastasis.  Knocking down 
miR-9 by 40% (Ruth White’s Thesis) did not significantly impact tumor growth in mouse 
SCCS (Figure 2.2A). B931-GFP tumors were more aggressive and had increased 
metastasis to the lung and chest wall (Figure 2.2 B, C) while knock down of miR-9 in the 
B931-Zip-9 tumors showed a significant reduction in metastasis (Figure 2.2 B, C). 
Histological analysis revealed that the tumors derived from B931-GFP cells, which 
express high levels of miR-9, showed spindle cell carcinoma (SPCC) histology while 
knockdown of miR-9 in B931-Zip-9 tumors was able to restore a less aggressive SCC 
histological morphology (Figure 2.2 D). However, knockdown of miR-9 was not able to 




























Figure 2.2 In vivo Tumor Growth Rate and E-cadherin Expression are Not Effected 
by MiR-9, but Metastasis and SPCC Tumor Morphology Are Effected.  
(A) MiR-9 knockdown in B931 cells (B931-Zip-9) did not alter tumor growth in 
immunosuppressed athymic nude mice. 2,500 B931-GFP (n=5) or B931-Zip-9 cells 
(n=6) were subcutaneously injected into athymic nude mice. Tumor growth was 
measured weekly. Error bars represent standard deviation. (B) Quantification of 
metastases showed reduced numbers of metastases in B931-Zip-9 mice (n=5) compared 
to B931-GFP control mice (n=6) (p=0.04 for both chest wall and lung metastases). 
Metastases were identified grossly and confirmed by H&E staining. (C) Examples of 
multiple metastases in the chest wall and lung developed from a B931-GFP mouse 
compared to a single chest wall metastasis in a B931-Zip-9 mouse. Arrowheads point to 
metastases in the thoracic cavity. (D) H&E staining showing B931-GFP cells formed 
SPCC, whereas a tumor derived from B931-Zip-9 cells reversed to a more epithelial 
morphology. Boxed area in each panel is magnified in lower pane. Scale bar=50 µm for 
upper panels.  (E) Immunofluorescence staining showing that knockdown of miR-9 in 
B931-Zip-9 tumors does not restore E-cadherin expression compared to B931-GFP 











cadherin, an EMT marker (Figure 2.2C). These data show that decreased miR-9 
expression decreases metastasis in these mouse SCCS tumors through a mechanism that 
likely does not involve altering EMT. 
To further elucidate the mechanism of metastasis, we looked at the ability of miR-
9 to alter cancer stem cell populations, which have been shown to be associated with 
metastasis [126, 127, 140-142]. Previous data has shown the miR-9 overexpression 
correlates with the Hoechst dye effluxing side population (SP) of cancer stem cells (CSC) 
(Ruth White's Thesis). To determine if knockdown of miR-9 alters the size of the SP in 
SCCS tumors, we injected 2,500 B931-GFP or B931-Zip-9 tumor cells into athymic nude 
mice, and harvested the tumors for Hoechst dye staining followed by flow cytometry. We 
found that tumors with knockdown of miR-9 tumors had more than a 10-fold reduction in 
SP+ cells (Figure 2.3 A, B). To confirm this result we examined levels of the ABCB1 
gene product, Mdr1, which has been shown to be increased in SP+ cells (Figure 2.3 C). 
Immunohistochemistry showed that Mdr1 staining is decreased in B931-Zip-9 tumors 
relative to staining in B931-GFP tumors. This data indicates that decreased miR-9 causes 
a decrease in SP+ cells in mouse SCCS tumors.  
To confirm that miR-9 levels influence the expression of ABCB1, we performed 
QRT-PCR analysis of RNA from B931-GFP and B931-Zip-9 cell lines. There was only a 
modest decrease in ABCB1a (Figure 2.4A). However, when ABCB1a expression in SP 
and non-SP sorted cells was analyzed, we found that B931-Zip-9 cells in both the non-SP 
as well as the SP population had decreased expression of ABCB1a as compared to B931-





Figure 2.3 SP Expansion is Caused by MiR-9 Overexpression. 
(A, B) Decreased SP population sizes in tumors derived from B931-Zip-9 cells 
compared to tumors derived from B931-GFP control cells (n=4, *p=0.007). Verapamil is 
used to validate specificity of SP sorting (A, B). (C) Mdr1 staining was decreased in 












Figure 2.4 Decreased MiR-9 Causes Decreased ABCB1a Expression in SP+ and 
Non-SP+ Cultured Cells, But Not Tumor Cells.  
(A-C) QRT-PCR for ABC transporters. (A) B931-GFP or B931-Zip-9 cultured cells 
show no change in ABCB1a expression.  (B) Non-SP+ and SP+ cells. B931-Zip-9 cells 
have a trend towards decreased ABCB1a expression relative to B931-GFP, but it is not 
statistically significant. (C) B931-Zip-9 tumors have a trend towards increased ABCG2 
expression relative to B931-GFP tumors (not significant), but other transporters show no 








altered in B931-Zip-9 tumors as compared to B931-GFP tumors, possibly because of the 
additional non-tumor stromal cells that are present (Figure 2.4C).  Alternatively, 
ABCB1a/b maybe differentially regulated at the translational rather than transcriptional 
level.  However, B931-Zip-9 tumors did have increased ABCG2 expression as compared 
to B931-GFP tumors (Figure 2.4C).  
 
Inhibition of ABC Transporters Decreased SCC Metastasis  
 
Previous studies have shown that SP cells in SCCs are chemoresistant [126]. If SP 
cells are also linked to metastasis, reducing or attenuating the properties of this 
population may reduce metastasis. To test this, we used three cell lines, B931-GFP, 
B911-GFP, and B911-miR-9. B911 is a tumor cell line derived from the same mouse 




 and had metastasis as well as an expanded 
SP+ cell population similar to the B931 tumor cell line (Figure 2.12). The B911 cell line 
had slightly lower miR-9 levels than the B931 line, so it was selected to create an 
overexpression model by transducing cells with lentiviral construct expressing either GFP 
or miR-9 (Figure 2.7). We then xenografted B931-GFP, B911-GFP, and B911-miR-9 
cells into athymic nude mice and treated tumor bearing mice with docetaxel, a 
microtubule inhibitor, alone or in combination with verapamil, which blocks the activity 
of the ABC transporters in SP cells. In addition to being an antagonist for ABC 
transporters, verapamil is more commonly known as an L-type calcium channel blocker 
that is used in patients to treat high blood pressure, cardiac arrhythmias, and headaches. 
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Figure 2.5 SP Expansion Can Be Targeted To Reduce Metastasis By Combined 
Treatment With Verapamil and Chemotherapy. 
(A, B) Treatment of tumor bearing mice with a combination of docetaxel and 
verapamil significantly reduced lung metastasis from tumors generated by (A) B931-GFP 
and (B) B911-GFP cells, but not B911-miR9 cells. (A) *p = 0.03 compared to control 
(vehicle only). No other conditions were statistically significant.  (B) P=0.02 compared to 
either docetaxel or verapamil. Additionally, B911-miR-9 tumors trended towards 
decreased metastasis as compared to B911-GFP tumors in all conditions. (C, D) 
Quantification of SP analysis from tumor B931-GFP or B911-GFP/B911-miR-9 tumor 
bearing mice treated with control (vehicle), docetaxel, verapamil, or combination. (C) 
B931-GFP verapamil treated tumors have significantly reduced SP relative to control. (D) 
B911-GFP and B911-miR9 tumors show no change in SP with drug treatment; however, 
B911-miR-9 tumors have significantly larger SP+ cell population relative to B911-GFP 
tumors.  (E) H&E staining of B931-GFP tumors show no difference in tumor morphology 












lung metastasis when mice were treated with docetaxel in combination with verapamil in 
B931-GFP tumor bearing mice (Figure 2.5A). A similar effect was seen in B911-GFP 
tumor bearing mice (Figure 2.5B). However, no change in metastasis was seen in B911-
miR-9 mice (Figure 2.5B). Additionally, the B911-miR-9 had decreased metastasis as 
compared to the B911-GFP mice (Figure 2.5B). This is in contrast to previous reported 
data in our lab (Ruth White Thesis). To determine the effectiveness of verapamil 
treatment in reducing SP+ cells, we analyzed the size of the SP+ cell population in these 
tumors. A reduction in the verapamil treated tumor SP+ cell population may indicate the 
verapamil causes a true decrease in the SP+ cell population, or it may indicate that 
systemic verapamil treatment is effective in blocking the ABC transporters necessary for 
efflux of Hoechst dye. We found the B931-GFP tumors that were treated with verapamil 
alone or in combination with docetaxel had reduced SP+ cell population (Figure 2.5C). 
Conversely, there was no change in the SP+ cell population in either B911-GFP or B911-
miR-9 tumors with this same drug treatment (Figure 2.5D). These data indicate that in 
certain tumors, verapamil effectively reduces the SP+ cell population; however, since 
B911-GFP cells had decreased metastasis without a reduction in the SP+ cell population, 
a more complex mechanism for the reduction in metastasis likely exists.  Examining drug 
treated B931-GFP tumor histology revealed that verapamil alone or in combination with 







SCCS Metastasis Had Altered Ploidy as Compared to the Primary Tumor  
 
As Hoechst dye binds to the minor grove of the DNA, SP analysis can be used to 
estimate the ploidy status of the cells being analyzed; diploid cells have lower intensity 
than tetraploid cells. The SP analysis of the B931 tumors indicated that these tumors are 
mostly tetraploidy (Figure 2.3A). To determine if metastasis from the B931-GFP tumors 
contained SP+ cells, we analyzed lung metastasis from B931-GFP tumors and compared 
them to the primary tumor. SP analysis showed that tumor cells from lung metastases of 




Figure 2.6 Lung Metastasis Had a Predominant Diploid Cell Population and SP, 
with a Primary Tumor that was Tetraploid.  
(A) Diploid cell population and SP+ cells in B931-GFP lung metastases. (B) B931-
GFP tumor from same mouse as lung metastases showing a large tetraploid cell 
population with correlating SP+ tetraploid cells. Verapamil is used to validate specificity 





Hoechst dye intensity (Figure 2.3D). This was in contrast to the predominant tetraploid 
population found in the primary tumor (Figure 2.3E). The main SP+ cells were also 
shifted from being tetraploid in the parental tumor to being diploid in the lung metastasis 
(Figure 2.3 D, E). While this data is preliminary, it shows that metastatic cells can have a 
different ploidy state than the primary tumor. 
 
High MiR-9 Expression Altered Numerous Pathways Potentially Involved in 
Mediating SCCS Metastasis  
 
To better understand the mechanisms driving miR-9 mediated metastasis in 
SCCS, we performed RNA sequencing analysis comparing B911-GFP and B911-miR-9 
cell lines. Additionally, we analyzed RNA from B931-GFP and B931-Zip-9 tumors 
grown in athymic nude mice. Table 2.1 summarizes some of the significant pathways that 
were altered.  
Several key pathways regulating interaction with the tumor microenvironment 
were found. When comparing cell lines or tumors with higher miR-9 levels to those with 
lower miR-9 levels, we saw increased the expression of several matrix metalloproteinases 
(MMPs) including MMP3/8/10/11/12/13/28 by up to 5.36 fold. In addition to altering 
MMP expression, higher miR-9 levels caused decrease in collagen expression of 12 
different collagens. The expression of four collagens (Col) Col14a1, Col11a1, Col1a2, 
Col4a6 was down regulated by more than 2 fold when comparing tumors or cell lines 
with higher miR-9 expression to those that had lower expression (-10.33, -7.27, -5.33, -
2.88 fold respectively). A few collagens, including Col6a1, Col6a2, and Col5a3 were 
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modestly up regulated (+1.63, +1.93, and +2.08 fold respectively). The combination of 
up regulated matrix metalloproteinases and down regulated collagens likely contributes to 
extracellular matrix breakdown and potential tumor invasion.  
Regulation of EMT is another key component to metastasis, and high miR-9 
levels altered the expression of several genes involved in regulating EMT. Zeb2 was up 
regulated in the miR-9 higher expressing tumor and cell line (+1.72 and +1.17 
respectively). Numerous genes regulating EMT were down regulated including Snai2 and 
Twist2 (-2.07 and -1.65 respectively). As genes regulating EMT are only modestly up or 
down regulated, it is unclear what impact this might have on tumor progression. 
Another category of genes that had altered expression was the family of cytokines known 
as C-X-C motif ligands (Cxcl). Several Cxcl cytokines were highly up regulated 
including Cxcl1, Cxcl2, Cxcl3, and Cxcl16 (+31.78, +22.77, +11.52, +3.07 fold 
respectively). Conversely, a few Cxcl cytokines had decreased expression including 
Cxcl14, which had a -3.77 and -13.8 fold decrease representing a decrease in both B931 
tumor and B911 cell line analyses. Cxcl10 was also decreased (-4.13 fold). As the Cxcl 
chemokines are modulators of inflammation and the immune response, these likely alter 
the tumor microenvironment to create a tumor promoting atmosphere, and may play a 
role in immune evasion. Additionally, TGF-α, which can interact with Cxcl secretion is 
up regulated in miR-9 higher expressing cells (+8.48 fold). Furthermore, Jak1/2/3 had 
modestly increased expression in the B931-GFP tumors (+1.18, +1.38, +1.82 fold 
respectively), indicating potential up regulation of the Jak/Stat pathway either in the 
tumor cells or in the tumor microenvironment is associated with high miR-9 levels. The  
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Table 2.1 mRNA Sequencing Analysis Revealed Altered Pathways Potentially 
Involved in miR-9 Mediated Metastasis. 
RNA sequencing analysis. Expression of B911-miR-9 relative to B911-GFP cell lines 
are in blue. Expression of B931-GFP relative to B931-Zip-9 tumors in brown. All values 








































Jak/Stat pathway can be activated by cytokines, including TGF-α. Taken collectively, 
these data indicate that miR-9 likely promotes a pro-inflammatory tumor 
microenvironment. 
VEGFa/b/c factors showed increased expression with higher miR-9 levels in the 
cell line comparison (+1.59, +4.25, +1.17 fold respectively) but lower VEGFc expression 
(-3.71) was seen in the tumor comparison. This conflicting result may be due to the  
presence of other cell types in the tumor, such as stromal or endothelial cells. It is also 
possible this result may be reflective of the different cell lines (B911 verses B931).  
Several other signaling pathways known to be involved in cancer progression had 
significant, but modest expression changes. MiR-9 caused a slight but significant down 
regulation of several components to Wnt signaling, in particular Wnt10a which had a -
3.61 fold decrease in tumors with higher miR-9 expression. Additionally, the TGFβ 
pathway had several key genes with altered expression, including up regulation of 
TGFβR3 and TGFβ1 (+2.17 and +1.34 respectively) and down regulation of TGFβ3 and 
TGFβ2 ligands (-3.72 and -3.56).  
Genes associated with CSCs were up regulated in B931-GFP tumors and B911-
miR-9 cells. The most highly up regulated were Aldh1a3, Abcb1b, and Sox4 (+3.25, 
+2.26, +2.03 respectively).  Furthermore, eight additional genes in the Aldh, ABC and 
Sox families were up regulated. This indicates that high miR-9 is associated with a more 
stem cell population. 
Finally, two putative miR-9 targets, Yap1 and α-catenin, showed slight down 
regulation in the B911-miR-9 cell line (-1.54 and -1.12 respectively). However, in the 
tumor, there was no significant difference in Yap1 and α-catenin was up regulated by 
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+5.00 fold. Increase α-catenin expression is in contrast to the decrease in the α-catenin 
staining that was observed in tumor samples. This will be further discussed in the 
discussion section. 
As an additional way to examine the data, we also looked at genes from the RNA 
sequencing data that were increased by miR-9 overexpression and decreased by miR-9 
knockdown. This analysis revealed five genes that have strong evidence of being 
regulated by miR-9, including down regulation of Cxcl14 and Col18a1, and up regulation 
of Jak2, Zeb2, and Abcb1b (Table 2.2). While all of these values were statistically 
significant, only Cxcl14 and Abcb1b had larger than two-fold changes. Additionally, the 
B911 data is in cell lines, as compared to the B931 data that is in tumors. These 
differences may have masked other important genes that are regulated by miR-9. 
 
Table 2.2 Genes Increased in MiR-9 Overexpression and Decreased in MiR-9 
Knockdown. 
RNA sequencing analysis. Expression of B911-miR-9 relative to B911-GFP cell lines. 
Expression of B931-Zip-9 tumors relative to B931-GFP tumors. All values are 
statistically significant (p < 0.05). 
 




Cxcl14 Cytokine 3.77 -13.8 
Col18a1 ECM Protein 1.65 -1.14 
Jak2 Jak/Stat -1.38 1.63 
Zeb2 EMT Regulation -1.72 1.13 




Corynebacterium Bovis Infection Decreased SCCS Tumor Initiation and Metastasis  
 
Environmental factors can influence tumor progression, but little research has 
been done on the impact of Corynebacterium Bovis (C. Bovis), a pathogen endemic to 
most animal facilities that causes a chronic bacterial dermatitis in athymic nude mice, on 
tumor xenograft studies. During the course of this study, some of the mice became 
infected with C. Bovis, allowing us to study the impact of this environmental influence 
on tumor progression. We found that C. Bovis infection can significantly decrease the 
tumor initiation of B931-GFP xenografts (Table 2.1). Additionally, tumor bearing mice 
that were C. Bovis positive had a much lower incidence of lung metastasis (Table 2.1). 
This is not true for all cell lines. B911-GFP and B911-miR-9 tumors showed no 
difference in tumor initiation or metastasis in clean versed C. Bovis positive mice. This 
data indicates the dramatic impact of C. Bovis on xenograft studies and highlights the 
importance of more research in this area.  
 
Table 2.3  C. Bovis Infection Decreased Tumor Initiation and Lung Metastasis. 
Flank injection of 5,000 B931-GFP tumor cells into athymic nude mice show 
decreased tumor initiation and lung metastasis in C. Bovis positive mice. Mice 
euthanized 4-6 weeks after tumor injection. 
 
 
Tumor Initiation Lung Metastasis 
 
# Mice % # Mice % 
C. Bovis Negative 34/40 85 14/15 93.3 





Additional Data Contributed by Other Lab Members 
 
MiR-9 Increased SP and Invasion but Inhibited Cell Cycle  
 










tumors with varying levels of miR-9 expression (Figure 2.7). We stably transfected a 
miR-9-1 pre-miRNA (System Bioscience) into B911 cells, a line with low intrinsic miR-
9 expression, to overexpress miR-9 and conversely, we used a “miRZip
TM
” (System 
Bioscience) anti-miR (Zip-9), to knock down miR-9 in B931cells, a line with higher 
intrinsic miR-9 expression. 
After confirming changes in miR-9 expression and activity in the cell lines after 
transfection (Figure 2.7), we examined the lines for changes in cell behavior after 
manipulation of miR-9 expression.  Since miR-9 was highly expressed in aggressive 
tumors, we examined if miR-9 affects tumor cell growth. Surprisingly, overexpression of 
miR-9 in the B911 line (B911-miR-9) slowed tumor cell growth in vitro compared to 
GFP transduced controls (Figure 2.8). Cell cycle analysis showed that the percentage of 
cells in the S phase was reduced by miR-9 overexpression but increased after knocking 
down miR-9 (Figure 2.8), indicating that miR-9 inhibits cell cycle progression. Next, we 
examined if miR-9 overexpression directly promotes invasion using Matrigel coated 
trans-well tissue culture plate assays. B911-miR-9 showed significantly increased 
invasion compared to GFP controls (Figure 2.9). Conversely, B931-Zip-9 cells showed a 










 tumors.  




 cell lines relative to wild 
type (WT) primary keratinocytes. *p=0.0003 compared to WT keratinocytes; #p=9x10
-8
 
compared to WT keratinocytes (n=3/group). (B) Increased expression of mature miR-9 in 




 cell line (B911) relative to GFP transduced 
control cells, measured by qRT-PCR (n=3/group). (C) Increased miR-9 activity 
repressing luciferase expression in the stably transduced B911 cell line (n=3/group, 
p=9x10
-9
). Activity was measured using a luciferase construct containing a miR-9 target 
sequence 3’ to the luciferase gene. (D) Abrogation of miR-9-mediated inhibition of 
luciferase expression in B931-Zip-9 cells (n=3/group, p=9x10
-5







Figure 2.8 Effects of miR-9 on Cell Growth and Cell Cycle Inhibition.  
(A) miR-9 overexpression inhibits B911 tumor cell growth in vitro. Cell proliferation 
was measured using a WST-8 colorimetric assay (n=3/group). (B) miR-9 overexpression 
decreases the percentage of cells in S-phase compared to control in B911 mouse tumor 
cell lines (p=2x10-4). (C) Knockdown of miR-9 in the B931 mouse tumor line increases 
the percentage of cells in S-phase (p=0.004). Each cell cycle assay was done in triplicate. 
(D) Matrigel invasion assays show increased invasion of B911-miR-9 cells compared to 
B911-GFP cells (p=6x10-5). (E) Increased invasion of Cal27-miR-9 cells compared to 







Figure 2.9 MiR-9 Promoted Invasion of Mouse and Human SCC.  
(A) Increased invasion in mouse B911-miR-9 cells compared to B911-GFP cells 
(p=6x10
-5
) (B) Reduced invasion in B931-Zip-9 compared to B931-GFP control cells 
(p=0.005). All invasion assays were performed in triplicate. Contributed by Ruth White. 
 
 
 (Figure 2.9). We then transplanted 1,000-2,500 B911 or B931 cells into flank skin of 
nude mice and analyzed tumor morphology and metastasis. Even though miR-9 showed 
growth inhibition in vitro (Figure 2.10), the rates of tumor formation from cells with 
miR-9 transfection did not significantly differ from parental cell lines (Figure 2.10), 
suggesting the microenvironment affects in vivo tumor growth. While both B911-GFP 
and B911-miR-9 cells developed SCCs with loss of E-cadherin and increased N-cadherin 
(Figure 2.11) and developed lung metastasis (not shown), morphological changes from 
poorly differentiated SCCs to SPCCs were only correlated with increased miR-9 
expression (Figure 2.11). To determine if miR-9 overexpression contributes to SP 
expansion, we performed SP sorting on the above tumors. The SP size was increased by 
more than 10-fold in B911-miR-9 tumors compared to B911-GFP tumors (Figure 2.12 A, 
B). Immunostaining revealed an increase in Mdr1 protein in B911-miR-9 tumors 






Figure 2.10 In vivo Tumor Growth Rate was Not Affected by MiR-9.  
MiR-9 overexpression in B911 tumor cells (B911-miR-9, n=3/group) did not alter 
tumor growth in immunosuppressed athymic nude mice. 1,000 B911-GFP or B911-miR-
9 cells were subcutaneously injected into athymic nude mice. Tumor growth was 







Figure 2.11 MiR-9 Overexpression Did Not Restore E-cadherin Expression, But 
Caused SPCC Tumor Morphology.  
(A) Immunofluorescence staining showing that both B911-GFP and B911-miR-9 
tumors express high levels of N-cadherin (Red) but do not express E-cadherin (Green). 
Scale bar = 50 µm. (B) H&E staining showing that miR-9 increased SPCC formation in a 
tumor derived from B911-miR-9 cells. Boxed area in each panel is magnified in lower 











Figure 2.12 SP Expansion is Caused by MiR-9 Overexpression. 
(A, B) Increased SP sizes in tumors derived from B911-miR-9 cells compared to 
tumors derived from B911-GFP control cells (n=3, *p=0.003). Verapamil is used to 
validate specificity of SP sorting (A, B). (C) Mdr1 staining was increased in B911-miR-9 
tumors compared to B911-GFP tumors and decreased in B931-Zip-9 tumors compared to 











Identifying MiR-9 Targets Involved in SP expansion, EMT and Metastasis in 
K15.Kras
G12D
.Smad4-/- SCCs  
 
MiR-9 has multiple known targets including both tumor suppressors and 
promoters. Among them, E-cadherin [177] and NFB1 [172, 208] are generally 
expressed in SCCs, whereas two other recently identified potential miR-9 target proteins 
Socs5 [178] and LIFR [209] are expressed at very low level in SCCs in general. Because 
miR-9 is not expressed in normal mouse skin [210] and microRNA regulation of target 









 SCCs that overexpress miR-9, NFB1 was still 
prominently expressed (data not shown), suggesting that either NFB1 is not a 
predominant miR-9 target in these cells or miR-9 mediated NFB inhibition can be 




 SCCs, such as loss of Smad4 
loss-associated inflammation [12]. E-cadherin, a known miR-9 target [177], was 
completely lost in tumors derived from B911-miR-9 cells or B931-GFP cells (Figure 
2.11A and 2.2E). Tumors derived from B931-Zip-9 cells, however, did not restore E-
cadherin expression (Figure 2.2E), despite the dramatic effect of miR-9 knock down on 
metastasis (Figure 2.2B, C) suggesting that miR-9 has additional targets linked to 





SCCs and lymph node metastases (data not shown) prompted us to examine if -catenin, 
which showed an inverse correlation with miR-9 in colon cancer cells [211], is a 























Figure 2.13 MiR-9 Targets α-catenin.  
 (A) Predicted duplex formation between human and mouse α-catenin 3’UTRs and 
miR-9. (B) Western blot analysis demonstrating decreased α-catenin in B911-miR-9 
tumor cells compared to B911-GFP tumor cells, and (C) demonstrating that α-catenin 
was barely detectable in B931-GFP tumor cells but was increased in B931-Zip-9 tumor 
cells. (D) Immunofluorescence showing patchy loss of membrane-associated α-catenin in 
a SCC derived from B911-GFP cells compared to complete loss in a B911-miR-9 derived 
SCC. B931-GFP tumors have complete loss of α-catenin. B931-Zip-9 tumors have patchy 
recovery of α-catenin but do not have fully restored membrane α-catenin. α-catenin was 
retained in SCC metastases derived from FaDu-GFP cells but lost in SCC metastases 
derived from FaDu-miR9 cells.  Sections were counterstained for Keratin 14 (K14) (red), 
which was essentially lost in tumors derived from B911 or B931 cells and their derived 












target, and hence its loss contributes to increased levels of Mdr1, we searched the 
TargetScan miRNA database and found -catenin is predicted to be a direct miR-9 target 
(Figure 2.13 A). Western analysis showed that B911-miR-9 tumor cells had a significant 
reduction in -catenin whereas B931-Zip-9 tumor cells had an increase in -catenin 
compared to their respective GFP controls (Figure 2.13 B, C). In addition, -catenin 
staining was present in the cell membranes of ~50% of cells in tumors derived from 
B911-GFP cells but was completely lost in tumors derived from B911-miR-9 cells 
(Figure 2.13 D). Conversely, expression of -catenin was barely detectable in B931-GFP 
tumors (Figure 2.13 D). In B931-Zip-9 tumors, -catenin staining was patchy in the cell 
membrane, but in general, membrane-associated -catenin was not restored (Figure 2.13 
D).  
Reduced E-cadherin and -catenin could explain increased EMT and invasion 
induced by miR-9 overexpression; however, inhibition of metastasis by miR-9 
knockdown without full restoration of -catenin and E-cadherin suggested additional 
players involved in miR-9 overexpression. Moreover, since neither E-cadherin nor -
catenin directly targets Abcb1 expression, the reduction in the SP size resulting from 
miR-9 knockdown cannot be explained by this mechanism. Because -catenin has been 
shown to mediate metastasis [212, 213] and target Abcb1 [121, 214], Anand Reddi in our 
lab examined whether reduced -catenin/E-cadherin caused -catenin nuclear 
translocation. In tumors derived from B911-GFP cells, -catenin was localized mainly in 
the cytoplasm (Figure 2.14 A), in contrast, tumors derived from B911-miR-9 cells 




















Figure 2.14 MiR-9 Promoted Nuclear Translocation of β-catenin that Contributed 
to Abcb1 Overexpression.  
 (A) Immunofluorescence of β-catenin (green) showing membrane staining in a 
primary K15.KrasG12D.Smad4-/- SCC.  Membrane staining was lost in passaged SCC 
and had increased nuclear β-catenin. SCC derived from B911-GFP cells shows 
cytoplasmic β-catenin, which became predominately nuclear in a B911-miR-9 tumor. A 
B931-GPF tumor shows cytoplasmic and sporadic nuclear β-catenin, whereas a B931-
Zip-9 tumor shows patchy restoration of membrane-associated β-catenin. Sections were 
-PCR 
showing siRNA knockdown of β-catenin in B911-GFP and B911-miR-9 cells. *p=0.03 
compared to scrambled siRNA control (n=3). (C) Knockdown of β-catenin reduces 
Abcb1a expression. *p=0.01 compared to B911-GFP transfected with scrambled siRNA 
(n=3); #p=0.03 compared to B911-miR-9 transfected with β-catenin siRNA (n=3).  













tumors showed both cytoplasmic and nuclear -catenin staining (Figure 2.14 A); 
however, nuclear -catenin was rarely observed in B931-Zip-9 tumors, and more 
strikingly, patchy restoration of membrane-associated -catenin was obvious (Figure 2.14 
A). To further study if activated -catenin contributes to increased Abcb1a expression, 
we knocked down -catenin in B911-miR-9 cells and B911-GFP control cells (Figure 
2.14 B), and assayed for Abcb1a transcripts. Knocking down -catenin significantly 




MiR-9 Increased Lung Metastasis by Expansion of the SP+ Cell Population  
 
Few models of mouse SCCS capable of metastasizing to the lung exist, so the 
model utilized in this study allowed for a unique opportunity to investigate the 
mechanisms underlying SCCS metastasis. MiR-9 causes aggressive lung and thoracic 
metastasis, which is demonstrated in this study by decrease metastasis upon knockdown 
of miR-9 (Figure 2.2C). High expression of miR-9 also increases the SP+ cell population, 
which is correlated with an increase in metastasis (Figures 2.3A, B; 2.12A, B, and Ruth 
White’s Thesis). However, we saw that very high SP+ cell populations (>50%) no longer 
correlated with an increase in metastasis, and in fact, decreased metastasis (Figure 2.5B). 
It is possible this effect is seen since miR-9 has been shown to decrease cell proliferation, 
likely due to induction of quiescent stem-cell properties ([172] and Figure 2.8). If miR-9 
levels become too high, perhaps the inhibition of proliferative cells decreases the number 
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of cells present that are capable of metastasizing to the lungs. Further evidence of 
decreased tumor growth rates associated with miR-9 overexpression is indicated by 
additional data (Ruth White’s Thesis and Chapter III).  
Preliminary data in this study suggest that the metastatic cell population and the 
SP+ cell population measured in this study may be different. SP analysis showed the 
primary tumor as predominantly tetraploid cells, while the lung metastases were diploid. 
This indicates that either the few diploid cells in the primary tumor are responsible for 
metastasis, or that the process of metastasis may cause the tumor cells to revert back to a 
pseudo-diploid state, a process known as depolyploidization (reviewed in [215]). While 
depolyploidization is not a well understood process, a recent study showed tetraploid 
tumor cells revert back to a pseudo-diploid state by multipolar mitosis that is dependent 
on P53 inhibition, and expression of MOS (also known as c-MOS), and has been 
associated with more aggressive tumors [216]. 
While studies have shown that SP cells in SCCs are chemoresistant, and they have 
properties that suggest they contribute to metastasis, there is little direct evidence on the 
role of SP cells in metastasis [126, 217]. Using the ABC transporter inhibitor verapamil 
in combination with docetaxel, we found that sensitizing SP cells to chemotherapy did 
decrease metastasis (Figure 2.5). This effect may have been due to increased killing of 
the SP+ cell population by decreasing their ability to efflux the chemotherapeutic. 
Alternatively, it may suggest that functional ABC transporters are necessary in the 
process of metastasis. We again saw no difference in metastasis in the highly expressed 
miR-9 tumors, likely for the same reasons discussed above, as well as an inability to 
demonstrate that the inhibitor was successfully blocking the ABC transporter in these 
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cells. Further studies investigating potential therapeutic opportunities utilizing this 
knowledge are warranted. 
 
MiR-9 Altered Expression of Genes to Potentially Enhance Invasion, Inflammation, 
Immune System Evasion and CSC Markers 
 
As a somewhat unique model of mouse SCCS capable of metastasizing to the 
lung, we decided to use the model in this study to investigate the mechanisms underlying 
SCCS metastasis. By comparing whole tumors or tumor cells with higher miR-9 
expression (B931-GFP, B911-miR-9) to lower miR-9 expression (B931-Zip-9, B911-
GFP) using RNA sequencing, we demonstrated several key factors that had altered 
expression. High miR-9 increased expression of seven MMPs with a coordinated 
decrease of 13 collagens. This combination would likely contribute to the ability of these 
cells to invade, as was seen in miR-9 higher expressing cells (this study, Chapter III, and 
Ruth White’s Thesis).  
Additionally, high miR-9 expression resulted in altered expression of many Cxcl 
cytokines. Of note, the cytokines Cxcl1/2/3 were highly up regulated. Cxcl1/2/3 have all 
been implicated in maintaining a pro-inflammatory tumor microenvironment, invasion, 
and metastasis [218-220]. Furthermore, Cxcl14 was highly down regulated. Studies 
indicate that Cxcl14 has a paradoxical role, but can behave as a tumor suppressor by 
acting as a chemoattractant for recruitment of dendritic cells [221, 222]. Decreasing 
Cxcl14 may allow SCCS tumors to evade the immune system. Alternatively, it may act as 
a tumor promoter, but the other gene expression alterations allow the tumors to overcome 
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its effect. TGFα, which is a mediator of cytokine expression and promotes invasion, was 
also up regulated. Further studies are necessary to clarify the role of these cytokines, and 
may allow for new therapeutic targets, or identification of additional SCCS markers. 
Not surprisingly, several markers and regulators of CSCs were up regulated with 
higher miR-9 levels. Genes in the ABC transporter family, Aldh family, as well as the 
Sox family were all up regulated. As data in this study shows, miR-9 was correlated with 
SP+ expansion (and Ruth White’s Thesis), which is mediated through the ABC 
transporter family members. However, the up regulation of Abcb1b represents a 
discrepancy between the data from the RNA Sequencing and QRT-PCR data. In the 
QRT-PCR data from B931-GFP and B931-Zip-9 showed no difference; however, in the 
RNA Sequencing data, it showed a 1.74 fold increase in the B931-GFP. It is likely that 
the RNA Sequencing data is more accurate, and a 1.74 fold change, while significant, is 
not a large change and may not have been detected given the primer set that was used for 
the QRT-PCR experiment.  
Aldh has also been suggested as a putative CSC marker in several cancer types, 
and may contribute to chemoresistance [223-225]. Several Sox genes, including Sox4, 
were up regulated with high miR-9 levels. The Sox genes are known regulators of stem 
cell properties, and Sox4 in particular has been investigated for its ability to enrich CSC 
populations and promote EMT [226, 227]. Collectively, this data indicates that several 
potential CSC populations may be enriched with miR-9 expression. It will be important 
to clarify the role of these CSCs, and if they are unique or represent overlapping cell 
populations in future studies.  
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The miR-9 target proposed by this work, α-catenin, was up regulated in the B931-
GFP tumor as compared to the B931-zip-9 tumor samples. This is opposite of what we 
observed in the immunofluorescent staining of the tumor sections, which showed a 
decrease in α-catenin staining. One possible explanation is that miR-9 does not cause the 
degradation of α-catenin mRNA, but does inhibit the translation of the mRNA into the 
protein. This could cause compensatory up regulation of α-catenin, but again, because of 
the miR-9 inhibiting translation, does not correlate with an increase protein levels. A 
luciferase assay using the 3’ UTR of α-catenin would help clarify this effect. 
 
Mechanisms Driving MiR-9 Metastasis and SP+ Cell Population Expansion 
 




 mice, increased miR-9 correlated 
with loss of E-cadherin and -catenin, the two previously reported potential miR-9 
targets associated with EMT and metastasis [177, 211]. It was not clear, however, 
whether loss of these adhesion molecules was the result of EMT, or direct targeting by 
miR-9. We found that miR-9 primarily targets -catenin. E-cadherin loss could occur 
either as a direct result of miR-9 overexpression, or a consequence of -catenin loss-
associated tumor progression.  
Our findings are consistent with reports that EMT promotes an increase in CSCs 
and metastasis in other cancer types [104, 228] and clinical observations that the reduced 
expression of -catenin and E-cadherin are prognostic indicators of poor survival and 
metastatic potential for SCCs [229-232]. However, loss of either E-cadherin or -catenin 
alone does not cause SCC metastasis [229-232]. Thus, additional events are required for 
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miR-9-mediated metastasis, and we have provided data implicating -catenin activation 
as that key event.  Restoration of membrane-associated -catenin after miR-9 knockdown 
did not alter tumor initiation and growth, suggesting that -catenin activation is not 
required for tumor initiation. However, restoration of membrane-associated -catenin via 
miR-9 knockdown was correlated with reduced metastasis, and knocking down -catenin 
reduced Abcb1a expression. Thus, increased nuclear -catenin appears to contribute 
greatly to miR-9-mediated expansion of metastatic CSCs. It is likely that loss of -
catenin and E-cadherin make it easier for -catenin to translocate to the nucleus since it is 
no longer anchored to the membrane. However, knocking down miR-9 prevented -
catenin nuclear translocation more efficiently than restoring membrane-associated -
catenin, suggesting that additional mechanisms are involved in -catenin activation.  
 
C. Bovis Infection Can Drastically Impact Tumor Xenograft Studies 
 
As an unfortunate event, some of the studies in this work got contaminated with 
C. Bovis. C. Bovis is endemic in the majority of animal facilities, and inherently 
extremely difficult to eradicate [233, 234]. Little data is publish on this bacteria, but a 
similar strain, Myobacterium Bovis, was being investigated as a potential cancer 
therapeutic for its activation of natural killer cells [235]. Many cell lines are not 
dramatically affected by C. Bovis infection; however, one of the cell lines, B931, saw a 
drastic decrease in both tumor initiation as well as lung metastasis.  Few researchers are 
aware of the impact this pathogen can have on studies, and it may have a larger impact on 
cancer experiments than what is fully understood. This data highlights the importance of 
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environmental influences on tumor xenograft studies, and further investigation of the 
mechanism by which C. Bovis decrease tumor initiation and metastasis may provide 
insight to both the larger impact this pathogen may be having on cancer research, as well 
as additional therapeutic treatments for SCCS.  
In summary, we demonstrate that miR-9 mediates SP+ cell expansion that is 
necessary but not sufficient to cause lung metastasis in mouse SCCS. Additionally, miR-
9 alters the expression of several key genes mediation invasion, inflammation, immune 
response, and CSC populations. MiR-9 decreases α-catenin, causing nuclear translocation 
of β-catenin and ABC transporter expression. Finally, this study also highlights the 
importance of environmental influences on mouse xenograft models.  
 
Recommended Future Experiments for This Project 
 
 
This project opens several avenues for continued research. As the SP+ cell 
population was important in regulating metastasis, it would be important to better 
understand the mechanism underlying this effect. Clarifying whether it is the SP+ cells 
that are metastasizing or whether metastasis requires the presence of SP+ cells would 
help elucidate this mechanism. Furthermore, determining the detailed mechanism of miR-
9 induced expansion of SP+ cell population and regulation of metastasis may provide 
insight into new therapeutic targets.  
Additionally, the expression changes seen in the RNA sequencing analysis need 
to be verified. There are several important pathways that are implicated in miR-9 
mediated metastasis. Further studies should elucidate the contribution of these individual 
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components to SCCS metastasis to better understand how this complex process is 
regulated. Several CSC markers were up regulated as well, and it may be important to 
clarify if these markers represent unique or overlapping CSC populations from the SP+ 
population examined in this study. Some data in this study indicate that different 
components of tumor progression, such as tumor initiation and metastasis, may be 
enhanced by difference CSC population (work in this chapter as well as Ruth White’s 
Thesis). Understanding the role of individual CSC populations may be critical for 
developing effective chemotherapeutics. Please see Chapter V for additional discussion 
on future directions for this project. 
Finally, C. Bovis is a major pathogen endemic to animal facilities. Further 
research on the mechanisms underlying the decreased tumor initiation and metastasis is 
important for understand the full impact this infection may be having on cancer research 






MICRORNA-9 REGULATES INVASION AND MIGRATION IN HUMAN HEAD 




Mechanisms contributing to metastasis in head and neck squamous cell 
carcinomas (HNSCCs) are still poorly understood. In this study, we show that 
overexpression of microRNA-9 (miR-9) contributes to increased migration and invasion 
in human HNSCC cell lines. There was a trend that miR-9 overexpression decreased 
tumor cell growth in human HNSCC xenografts. FaDu-miR-9 tumors had a more 
aggressive morphology, and showed loss of α-catenin staining. However, there was no 
difference in the rate of metastasis to cervical lymph nodes in the miR-9 overexpressing 
human HNSCC xenografts. Analysis of SP+ cells showed that miR-9 had either no 
change or decreased human HNSCC SP+ cell populations in cultured cells as well as 
tumor xenografts. Our data reveal that miR-9 overexpression in human HNSCC increases 
migration and invasion of these cells, but has no effect on SP+ cancer stem cells or the 




One aspect of HNSCC that is poorly understood is the mechanism underlying 
metastatic disease. Advanced HNSCCs that metastasize have a very poor prognosis, so 
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understanding the mechanisms underlying this disease process is important to potentially 
improving outcomes for these patients. Established data discussed in Chapter II, miR-9 
mediates metastatic potential in murine SCCS. Additionally, previous unpublished data in 
our lab done by Gangwen Han shows that miR-9 positive cells are increased in metastatic 
human primary HNSCCs and HNSCC metastasis (Table 3.1 and Figure 3.1).   
While miR-9 regulates metastasis in murine SCCS, and is associated with 
metastasis in human samples of HNSCC, it is unclear if miR-9 has a causal role in 
regulating metastasis in human HNSCC. In the current study, we provide evidence that 
miR-9 contributes to increased migration and invasion of human HNSCC, but is not 
sufficient to regulate metastatic potential of these cells. 
 
Table 3.1  Increased MiR-9 in Human SCC Metastases.  
MiR-9 positive cases are determined by in situ hybridization using a miR-9 specific 
probe. Fisher’s exact test is used to calculate p values.  *p=0.0001 compared to non-
metastatic SCC in the same column. #p=0.0001 compared to normal tissue in the same 
column. Typical images are presented in Figure 3.1. Table courtesy of Gangwen Han. 
 
 
Tissue Source Total Cases Negative Staining Positive Staining 


























Figure 3.1 MiR-9 is Expressed in Human SCC Metastases.  
 (A) Representative miR-9 in situ hybridization showing no miR-9 expression in non-
malignant oral mucosa and positive miR-9 staining (blue) in SCC metastasis.  Upper 
panels: whole tissue section; Lower panels: magnified sections from upper panels. The 
arrow points to an example of a nest of miR-9 positive cells. (B) Increased miR-9 in 
metastatic human primary SCCs transplanted into athymic nude mice (p=0.04). MiR-9 
expression was measured by qRT-PCR and tumors were grouped into lymph node 
negative (n=4) or positive (n=8) by TNM staging. Diamonds represent individual tumors, 




















MiR-9 Caused Increased Migration and Invasion of Human HNSCC  
 
To determine if miR-9 effects human SCCs similar to mouse SCCs, we 
transfected lentiviral vectors encoding miR-9-1 pre-miRNA into the FaDu cell line, 
which is a human head and neck SCC lines with genetic loss of  Smad4 [12], similar to 
that of the mouse SCCS used in chapter II (FaDu-GFP and FaDu-miR-9 cell lines 
courtesy of Ruth White). Additionally, we transfected two human HNSCC cell lines 
derived from lymph node metastasis, M3a2 and M4e (a generous gift from Cun-Yu 
Wang’s laboratory), which have been shown to have a measureable SP+ cell population 
in culture [126].  After confirmation that these cell lines had increased expression of 
miR-9 (Figure 3.2A, B), we assessed the ability of miR-9 overexpression to influence the 
migratory and invasive properties of these cell lines. We found that M3a2-miR-9 cell had 
increased the migration and invasion, but M4e-miR-9 cells had increased the migration as 
compared to GFP expressing controls (Figure 3.2 C-F). Ruth White showed similar data 
indicating that miR-9 overexpression increased migration and invasion of FaDu and 
Cal27 cells (Ruth White’s Thesis). 
 
MiR-9 Did Not Alter the SP+ Cell Population in M3a2 or M4e Cell Lines 
 
In Chapter II, miR-9 overexpression correlated with increased in the CSC 





Figure 3.2 MiR-9 Increased Migration and Invasion in Human HNSCC.  
(A, B) QRT-PCR confirming miR-9 overexpression (A) M3a2-miR-9 compared to 
M3a2-GFP (B) M4e-miR-9 compared to M4e-GFP. (C, E) Boyden chamber migration 
assay of (C) M3a2-miR-9 compared to M3a2-GFP (D) M4e-miR-9 compared to M4e-
GFP. (D, F) Boyden chamber invasion assay with matrigel of (C) M3a2-miR-9 compared 
to M3a2-GFP (D) M4e-miR-9 compared to M4e-GFP. All migration/invasion assays 




overexpression was able to recapitulate this increase in CSC in human HNSCC, we 
analyzed the SP+ cell population in miR-9 overexpression cell lines. M4e-miR-9 had a 
decreased SP+ cell population as compared to M4e-GFP cells (Figure3.3A, E-G). 
However, this same effect was not seen in the M3a2-miR-9 cells, which showed no 
difference in the SP+ cell population (Figure 3.3A-D). FaDu cell lines did not have a 
measureable SP+ cell population (Figure 3.4). Another remarkable finding during the SP 
analysis was that verapamil, an ABC transporter inhibitor as well as an L-type calcium 
channel blocker, that was used successfully to block to SP+ cell population from 
effluxing Hoechst dye in the mouse SCCS cell was unable to block the SP+ cell 
population in the M3a2 or M4e cells (Figure 3.5A). However, another ABC transporter 
inhibitor, Reserpine, (also a vesicular monoamine transporter inhibitor) was able to 
successfully inhibit the SP+ cells from effluxing Hoechst dye (Figure 3.5B, C). This may 
indicate that the subtype of ABC transporters responsible for Hoechst dye efflux varies 
from mouse to human. 
 
MiR-9 Slowed Tumor Growth Rate and Increased Tumor Initiation, but was Not 
Sufficient to Alter Metastasis of Human HNSCC Cell Lines 
 
As indicated in Chapter II, miR-9 overexpression in mouse SCCS altered 
numerous factors that interact with the tumor microenvironment (Table 2.1). Thus, it is 
possible that miR-9 overexpression in human HNSCC would cause more robust changes 
in an in vivo model. To investigate this, we orthotopically injected 150,000 FaDu-GFP or 






Figure 3.3 MiR-9 Decreased the SP+ Cell Population in Human HNSCC.  
(A) Quantification of SP size in M3a2-miR-9 and M4e-miR-9 cells showing decreased 
SP+ cells in M4e-miR-9 cells. (B-G) Representative SP flow data. (B) M3a2-GFP (C) 
M3a2-miR-9 (D) Reserpine control of M3a2-GFP. (B) M4e-GFP (C) M4e-miR-9 (D) 













Figure 3.4 FaDu Cells Did Not Have an SP+ Cell Population, Regardless of MiR-9 
Status.  
Representative SP flow cytometry of (A) FaDu-GFP and (B) FaDu-MiR-9 cell lines 









Figure 3.5 Reserpine but Not Verapamil was Able to Block SP+ Cell Population in 
Human HNSCC.  
Representative flow cytometry data. (A) M3a2-GFP in the presence of Verapamil 
(100ug/ul). (B) M3a2-GFP in the presence of Reserpine (50ug/ul). (C) M3a2-GFP with 








Table 3.2  MiR-9 Increased Tumor Initiation. 
Orthotopic injection of 250,000 M3a2-GFP, M3a2-miR-9, M4e-GFP or M4e-miR-9 
tumor cells into athymic nude female mice. MiR-9 overexpression tumors cells have 






in the floor of the mouth of athymic nude female mice. Both M3a2-miR-9 and M4e-miR-
9 tumor cells showed increased tumor initiation (Table 3.2). Although not statistically 
significant, miR-9 overexpressing tumors grow more slowly in all three human HNSCC 
cell lines (Figure 3.6A-C). Furthermore, FaDu-miR-9 tumors had similar lymph node 
metastatic rates as compared to FaDu-GFP, and none of the M3a2 or M4e tumors had 
detectable lymph node metastases. Although there was no difference in the primary 
tumor morphology in H&E staining (Figure 3.6D), FaDu-miR-9 lymph node metastases 
were more wide-spread and showed a more aggressive, EMT-like morphology (Figure 
3.6E). FaDu-miR9 lymph node metastases retained E-cadherin expression similar to 
FaDu-GFP lymph node metastases (Figure 3.6F). However, FaDu-miR-9 lymph node 
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Figure 3.6 MiR-9 Decreased Growth Rate and Caused a More Aggressive 
Morphology in Metastatic Lymph Nodes in Human HNSCC.  
(A-C) MiR-9 slows growth rate of orthotopic tumor xenografts in athymic nude 
female mice. (A) FaDu-GFP and FaDu-MiR-9 (150,000 cells/injection) (B) M3a2-GFP 
and M3a2-miR-9 (250,000 cells/injection) (C) M4e-GFP and M4e-miR-9 (250,000 
cells/injection). (D) H&E staining of M3a2-GFP, M3a2-miR-9, M4e-GFP, and M4e-
miR-9 primary tumor xenografts. (E) H&E staining showing a representative metastasis 
derived from FaDu-GFP cells exhibiting clustered epithelial cell morphology, whereas a 
metastasis from FaDu-miR-9 cells displayed poorly differentiated and EMT morphology 
(more obvious in the magnified panels). The scale bar=50 µm for top two panels. (F) 
Immunofluorescence of membrane-associated E-cadherin and α-catenin in tumors 
derived from FaDu cells transduced with GFP or miR-9. K14 was used to counterstain. 

















Figure 3.7 MiR-9 Increased Mdr1 Protein in Human HNSCC Lymph Node 
Metastasis.  
(A-B) Representative SP flow cytometry. FaDu orthotopic xenografts do not have an 
SP+ cell population. (A) FaDu-GFP. (B) FaDu-miR-9. (C) Immunohistochemistry of 
FaDu-MiR-9 lymph node metastasis show increased Mdr1 staining relative to FaDu-GFP 














MiR-9 Increased Mdr1 in Metastases, But Did Not Alter Primary Tumor SP+ Cell 
Populations  
 
To determine if miR-9 is able to alter the SP+ cell population in vivo, we analyzed 
the above tumors using flow cytometry of Hoechst dye efflux. Similar to the cultured cell 
data previously described (Figure 3.4), FaDu-GFP and FaDu-miR-9 tumors did not have  
a detectable SP+ cell population (Figure 3.7A, B). Surprisingly, the M3a2-GFP, M3a2-
miR-9, M4e-GFP and M4e-miR-9 tumors did not have a detectable SP+ cell population 
either (Figure 3.8A, B). This was especially interesting since the cell line for all of these 
conditions had a fairly large SP+ population (Figure 3.3). As all of the M3a2 and M4e 
tumors are extremely necrotic, it is possible the debris from the dead cells interfered with 
the Hoechst dye staining. To eliminate this variable, these tumors were sorted using 
propidium iodide to eliminate dead cells prior to staining with Hoechst dye. However, all 
of the M3a2 and M4e tumors still did not have a detectable SP+ cell population (Figure 
3.8C, D). This likely indicates that the selected human HNSCC tumors do not have an 
SP+ cell population under the conditions of this study. Immunohistochemistry of FaDu-
miR-9 lymph node metastases showed increased Mdr1 staining as compared to FaDu-
GFP lymph node metastases (Figure 3.7C). This indicates that while the primary tumor 
did not have increased ability to efflux Hoechst dye, which is mediated in part by Mdr1, 










Figure 3.8 M3a2 and M4e Tumors Did Not Have an SP+ Cell Population, 
Regardless of MiR-9 Expression.  
(A-D) Representative SP flow data. (A, C) M3a2-GFP SP analysis of Hoechst dye 
staining whole tumor (B,D) M3a2-miR-9 SP analysis of Hoechst dye staining live cells 
only (A-D) Reserpine was used to validate specificity of SP sorting. Preliminary analysis 









Additional Data Contributed by Other Lab Members 
 
MicroRNA-9 Contributed to HNSCC Invasion  
 
To determine if miR-9 effects human SCCs similar to mouse SCCs, we also 
transfected lentiviral vectors encoding miR-9-1 pre-miRNA into FaDu and Cal27 cell 
lines (Figure 3.9), both of which are human head and neck SCC lines with genetic loss of  
Smad4 [12].  
Next, we examined if miR-9 overexpression directly promotes invasion using 
Matrigel coated trans-well tissue culture plate assays. B911-miR-9, FaDu-miR-9 and 










 tumors.  
 (A) Increased mature miR-9 expression in stably transduced FaDu cell lines relative to 
GFP transduced FaDu cells, measured by qRT-PCR (n=3/group, *p=0.007). (B) 
Increased mature miR-9 expression in stably transduced Cal27 cell lines relative to GFP 
transduced controls (n=3/group, *p=2.5x10
-7






Figure 3.10 MiR-9 Promoted Invasion of Mouse and Human SCC.  
 (A, B) Increased invasion in human FaDu-miR-9 and Cal27-miR-9 cells as compared 
to FaDu-GFP and Cal27-GFP cells (p=0.005 and P=0.0005 respectively). All invasion 





MiR-9 Positive Cells are Increased in Metastatic Human Primary SCCs and SCC 
Metastasis  
 
It has been reported that miR-9 is frequently methylated in human cancers, 
including SCCs, and as such miR-9 has been suggested to be a tumor suppressor [236-
238]. The effect of miR-9 on the metastatic behavior of SCCs observed in our animal 
model and in the human SCC cell lines prompted us to examine whether miR-9 was 
elevated in human SCCs. In our lab, Gangwen Han performed in situ hybridization to 
detect miR-9 in tissue arrays of human SCCs and SCC metastases (Biomax). In normal 
head and neck tissue, miR-9 positive cells were undetectable (Figure 3.1 A); however, in 







Figure 3.11 MiR-9 is Expressed in Human SCC Metastases and Correlated with 
Loss of α-catenin and Increased Expression of Mdr1.  
 (A) miR-9 expression in SCC metastases correlated with α-catenin loss and increased 
expression of Mdr1. Each image row is from consecutive tissue sections. Top row: miR-9 
negative cells retained membrane E-cadherin and α-catenin, with no Mdr1 staining.  
Middle row: an example of α-catenin loss with retention of E-cadherin and increased 
Mdr1 staining in miR-9 positive cells.  Bottom row: an example of both α-catenin and E-
cadherin loss and increased Mdr1 staining in miR-9 positive cells.  The scale bar=50 µm 












Table 3.3  Summary of Staining Patters for α-catenin, E-cadherin and Mdr1 
proteins in MiR-9-Negative and Positive Cases of Human SCC Metastasis. 
Significance determined using Fisher’s Exact Test 
*Loss of α-catenin in miR-9 positive vs. miR-9 negative cases p=0.003 
#Loss of α-catenin compared to loss of E-cadherin in miR-9 positive tumors p=0.016. 
**Loss of both α-catenin and E-cadherin in miR-9 positive cases compared to miR-9 
negative p=0.045. 
***Mdr1 positive cases in miR-9 positive cases vs. miR-9 negative cases p=0.0001 
No significant difference in E-cadherin staining between miR-9 positive and miR-9 



































positive cells (not shown). This low incidence of miR-9 positive tumors is consistent with 
the recent finding that miR-9 is often methylated in SCCs [238]. In contrast, however, 
67% of SCC lymph node metastatic lesions contained miR-9-positive cells (50/75, Table 
3.1, Figure 3.1 B). 
The loss of -catenin but not E-cadherin in lymph node metastases (data not 
shown) and in primary tumors derived from FaDu-miR-9 human SCC cells (Figure 3.6 F) 
prompted us to examine if -catenin, which showed an inverse correlation with miR-9 in 
colon cancer cells [211], is a predominant miR-9 target in SCCs. Using the same SCC 
metastasis tissue array used in Figure 3.1 A, we stained for -catenin and E-cadherin, and 
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examined their correlation with miR-9 status.  We found that loss of E-cadherin occurred 
at similar rates between miR-9 negative and miR-9 positive cases (Figure 3.11, Table 
3.3). In contrast, -catenin loss increased significantly in miR-9 positive cases compared 
to miR-9 negative cases (Figure 3.11, Table 3.3). Further, immunostaining for Mdr1 in 
the SCC arrays revealed that Mdr1 positive cells were rarely detected in primary human 
SCCs (not shown), but were frequently detected in metastatic SCC lesions in sporadic 
patterns similar to miR-9. Cases with positive Mdr1 staining correlated with miR-9 




MiR-9 Increased Migration and Invasion of Human HNSCC without Increasing the 
SP+ Cell Population In Primary Tumors 
 
Consistent with data presented in Chapter II, the current study demonstrates that 
miR-9 overexpression alone was able to increase the migration and invasion of human 
HNSCC cell lines. However inconsistent with data gathered in mouse SCCS, miR-9 was 
not sufficient to increase the SP+ cell population, and in fact, the M4e-miR-9 cell line 
had a decreased SP+ cell population. The disconnect between the migratory and invasive 
properties of cells and an increased SP+ cell population suggests that in human HNSCC, 
these processes can be disconnected; an increase in SP+ cells is not necessary for 
increased migration and invasion of human HNSCC tumor cells. It is noteworthy that 
M4e-miR-9 cells did not show a difference in the invasion, and it was this same cell line 
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that had a decreased SP+ cell population. This provides further evidence that these two 
events are disconnected. It is likely that there are other mechanisms mediated by miR-9 
that are responsible for the migratory and invasive properties of miR-9 overexpression 
cells.  
FaDu lymph node metastasis showed an increase in MDR1 staining, even though 
the primary tumors did not, and the primary tumors did not have an increase in the SP+ 
cell population. While it would have been interesting to examine the SP+ cell population 
in the lymph node metastasis, it is not feasible given the limited amount of tissue 
available. LCM followed by QRT-PCR would be one way to further examine if the 
metastatic tumor cells have increased ABC transporters.  
 
MiR-9 Increased Tumor Initiation, Decreases Tumor Growth, and Did Not Alter 
Metastasis 
 
Overexpression of miR-9 in human HNSCC caused an increase in tumor 
initiation, but a decrease in tumor growth. One likely explanation for this is that miR-9 is 
increasing the CSC properties of the tumor cells. As the SP data indicates, miR-9 does 
not expand the SP+ stem cell population; however, this only represents a single CSC 
population. It is possible that in human HNSCC, miR-9 expands CSCs with slightly 
different properties that do not overlap with SP+ cells. An increase in CSCs would 
expectedly cause an increase in tumor initiation, and may likely decrease tumor growth as 
CSC are often quiescent or have slower cycling than non-CSCs.  
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MiR-9 did not alter the metastatic rate of human HNSCCs. This is surprising 
given the data linking miR-9 and metastasis in the previous chapter. It is possible that this 
also relates to expansion of a CSC population that is not associated with metastatic 
disease. However, miR-9 overexpressing metastatic tumors did have a more aggressive 
morphology and expressed more Mdr1. Perhaps more mutations than what are present in 
the parental human HNSCC cell line that were used are necessary for increased ABC 
transporters (and Mdr1 protein). It is possible that the metastatic HNSCCs gained enough 
mutations to allow for higher expression of these genes.  
 
MiR-9 Targets α-Catenin in Human HNSCC Metastasis 
 
Data in Chapter II indicated that α-catenin was a target of miR-9 in mouse SCC, 
but we wanted to confirm this was true in human HNSCC. Using human SCC cell-
derived tumors or metastatic SCCs which still partially retain adhesion molecules, we 
found that miR-9 primarily targets -catenin, since loss of -catenin was more 
pronounced than loss of E-cadherin in miR-9 transduced FaDu tumors. Further, in human 
SCC metastases, loss of both α-catenin and E-cadherin were more frequently observed in 
miR-9 positive cases than in miR-9 negative cases. Our findings are consistent with 
clinical observations that the reduced expression of -catenin and E-cadherin are 






Comparison between Mouse and Human Models 
 
The inconsistencies between mouse and human miR-9 models were unexpected 
finds (Table 3.4). The increase in SP+ cell populations seen in mouse SCCS and the 
decrease or no change seen in human HNSCC is one of the major discrepancies. There 
are several possible explanations for this inconsistency. The difference seen could be due 
to inherent properties of mouse verses human tumor cells. One piece of evidence for this 
is that the human SP+ cell population was not blocked by verapamil, but was blocked by 
reserpine. As these drugs target slightly different subpopulations of ABC transporter, it is 
likely that the effectiveness of the transporter is influenced by the ABC expression profile 
of the tumor cells. It is just as likely that the differences seen are due to tumor-type 
variations, as we are comparing SCCS to HNSCC. It would be important to clarify which 
of these components accounted for the observations in these studies.  
Another inconsistency seen between these models was α-catenin loss and 
increased MDR1 staining was seen in primary tumors in the mouse SCCS model; 
however, these same staining patterns were only seen in human HNSCC metastasis. This 
data suggests that while miR-9 might contribute to α-catenin loss and subsequent 
increase in MDR1, it is not sufficient to cause this effect in vivo. It is likely that 
additional cooperative mutations are necessary to achieve this phenotype. This might also 
be the explanation for why the mouse SCCS overexpression miR-9 tumors were more 
metastatic, while the human HNSCC did not have a difference in the metastatic rate. 
Again, miR-9 is likely a component of the metastatic process, but additional mutations 
are necessary to create the metastatic phenotype. 
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Table 3.4  Data Summary of MiR-9 Contributions to Mouse SCCS as Compared to 
Human HNSCC. 
Summary of the miR-9 data collected in both chapters II and III. All values below are 
expressed in terms of the higher miR-9 condition relative to the lower miR-9 condition 
(↑= increase, ↓ = decrease, Ø = no change). Values that were significant are indicated, as 
well as values that need more data for a definitive conclusion. ** Data was contributed by 
Ruth White. 
 
Effect of High miR-9 Expression Summary 



























There is an alternative explanation for the differences seen in the HNSCC verses 
SCC models. It is possible the cells have different relative levels of available miRNA 
processing machinery. Levels of other miRNAs as well as the rate of productions of this 
machinery within a particular cell type can both influence the availability of miRNA 
processing and degradation proteins. If the levels of other miRNAs are substantially 
different between the mouse and human model, it is possible this could account for the 
difference we saw. 
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In summary, we found that miR-9 increases the invasion of human HNSCCs 
independent of SP+ size and miR-9 increases human HNSCC tumor initiation while 
decreasing tumor growth. These data show key differences in the response to miR-9 in 
human HNSCC as compared to mouse SCCS discussed in Chapter II. 
 
Recommended Future Experiments for This Project 
 
 There are several key experiments that could be done to further the work 
presented in this chapter. Clonogenic assays of the miR-9 overexpressing cells might 
produce interesting findings. Another area in this project that needs further work is to 
determine the different ABC transporters expressed in human versus mouse cells, and the 
impact this may have on chemotherapy. Many studies conducted in mice that show 
positive results fail when translated into human trials. It is possible that the difference in 
ABC transporters could be one aspect of these studies that contributes to this pattern. 
Having a better understanding of the difference between mouse and human ABC 
transporters may allow for better mouse models and more successful drug trials.  
 Finally, this chapter and chapter II highlight key differential responses to miR-9 
overexpression between mouse SCCS and human HNSCC. It would be important to 
determine if the difference seen are from the difference between skin and head and neck 
SCC, or if the variation is due to species-specific properties. Generation of a mouse 




 mutation would be essential in answering 





SUBPOPULATIONS OF FIBROBLASTS WITH TGFβRII DELETION 





The contribution of the tumor microenvironment has increasingly been shown to 
play a role in tumor metastasis and progression. Genetic mutations in the tumor stroma 
may contribute to tumor progression, and can be utilized as a tool to better understand 
factors that create a tumor-promoting microenvironment. Deletion of the transforming 
growth factor beta receptor two (TGFβRII) is one spontaneous mutation that has been 
reported in stromal fibroblasts in head and neck squamous cell carcinoma (HNSCC). 
Additionally, subpopulations of fibroblast identified using different promoter may 
differentially regulate tumor properties. In the present study, we generated mouse 
fibroblasts with a fibroblast-specific TGFβRII deletion driven by the collagen type 2a 
promoter or the fibroblast specific protein-1 (FSP1) promoter. We found that conditioned 
media from FSP1 driven but not Col1a2 driven TGFβRII-deleted fibroblasts increased 
the migration and invasion of HNSCC cell lines. Additionally, co-culture of TGFβRII-
deleted fibroblasts and HNSCC tumor cells caused no change in colony formation in soft 
agar assays. Orthotopic xenografts of HNSCC cells co-transplanted with TGFβRII-
deleted fibroblasts showed no difference in growth or local lymph node metastasis. 
Additionally, chemically-induced carcinogenesis was not altered in Col1a2.ΔβRII mice. 
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Microarray analysis revealed that Col1a2 TGFβRII-deleted fibroblasts did not show up 
regulation of HGF or TGFα, two previously identified growth factors secreted by FSP1 
TGFβRII-deleted fibroblast. Our data suggests that subpopulations of fibroblasts that 




While it is generally accepted that fibroblasts represent a heterogeneous 
population, little work has been done to investigate the importance of this heterogeneity 
in the tumor microenvironment. However, studies have examined the importance of 
fibroblasts to tumor initiation and progress. A key experiment done by Bhowmick et al 
used TGFβRII deletion in fibroblast specific protein- 1 (FSP1) cells to show that this 
mutation in fibroblasts was sufficient to cause spontaneous forestomach tumors [190]. 
While there is controversy over the validity of fibroblastic mutations contributing to 
carcinogenesis, two further studies in the HNSCC field showed that CAFs captured by 
LCM or grown in culture had either loss of heterozygosity (LOH) or down regulation of 
the TGFβRII [200, 201]. These studies gave the foundation for our lab to make a mouse 
model utilizing a different fibroblast promoter, Collagen type 1α2, to drive the deletion of 
TGFβRII specifically in fibroblast, and examining the influence of this mutation in 
HNSCC tumor initiation and progression. In this study we provide evidence that 
TGFβRII deletion in distinctive subpopulations of fibroblasts differentially regulates 





Fibroblasts Derived from Col1a2Cre.TGFβRIIf/f Have Disrupted TGFβ Signaling  
 
 We crossbred Col1a2CreER mice with TGFβRII floxed mice (TGFβRIIf/f) and 
mice with a floxed stop codon upstream of β-galactosidase (Rosa26) as a reporter. 
Treatment of 3 week old mice for 5 days with oral Tamoxifen caused homozygous 
deletion of the floxed TGFβ alleles and homozygous deletion of the stop codon upstream 
of β-gal, effectively deleting TGFβRII and expressing β-gal specifically in collagen type- 
1 alpha 2 producing fibroblasts (henceforth referred to as Col1a2.ΔβRII fibroblasts) 
(Figure 4.1 A). Recombination in oral tissue was confirmed by staining for β-




Figure 4.1  Generation of Col1a2.TGFβRIIf/f.Rosa26 Trigenic Mice and Evidence of 
Oral Recombination by β-galactosidase Staining. 
(A) Schematic of the mating strategy to generate K15.KrasG12D.Smad4-/- trigenic 
mice. (B) β-galactosidase staining of oral buccal and tongue tissues showing positive blue 





While a similar mouse model made previously using fibroblast-specific protein 1 
(FSP) to drive the knockout of TGFβRII in fibroblasts developed spontaneous 
forestomach SCCs and had prostatic hyperplasia [190], the Col1a2.ΔβRII mice in our 
model did not have any identifiable phenotype up to a year after recombination induction 
(data not shown, courtesy of Steven Malkoski). To help understand the difference in 
these mouse models, we obtained a Tgfbr2
fspKO.GFP 
mouse (generous gift from Harold 
Moses’ laboratory) to generate buccal fibroblasts that utilize FSP to drive Cre expression 
 
Figure 4.2  Generation of Col1a2.TGFβRIIf/f.Rosa26 Fibroblast Cell Lines Showed 
Evidence of Oral Recombination by β-galactosidase Staining, PCR, and QRT-PCR. 
(A) β-galactosidase staining of passage 5 of primary cultured buccal fibroblast from 
either TGFβRII
f/f 
Rose26 or Col1a2. TGFβRII
f/f 
Rose26 mice treated with Tamoxifen. (B) 
Quantification of percent of cells with visible β-galactosidase staining. (C) PCR of 
TGFβRII recombination showed presence of TGFβRII recombination band in all cell 
lines from Col1a2. TGFβRII
f/f 
Rose26 mice. (D) QRT-PCR of WT, Col1a2.ΔβRII, and 







and recombination of homozygous floxed TGFβRII (henceforth referred to as FSP.ΔβRII 
fibroblasts). Buccal, tongue, lung, and skin tissues were harvested from WT, 
Col1a2.ΔβRII, or Tgfbr2fspKO.GFP  mice and cultured to enhance the fibroblast population. 
Staining for β-galactosidase in cultured Col1a2.ΔβRII as compared to WT fibroblasts 
showed 75-85% of buccal, lung, and skin fibroblasts contained positive staining, 
suggesting that the majority of these fibroblast had genetic recombination; however, 
tongue fibroblasts did not show more than approximately 50% recombination (Figure 
4.2B). This suggests that there might be different ratios of fibroblast subpopulations in 
different endogenous location. Because of the low recombination, buccal fibroblasts were 
used for the remainder of the studies. PCR for the recombination product confirmed 
deletion of TGFβRII, and QRT-PCR for TGFβRII revealed greater than 95% decrease in 
expression in Col1a2.ΔβRII and  FSP.ΔβRII buccal fibroblasts as compared to wild-type 
(WT) fibroblasts (Figure 4.2D).  
To verify if fibroblasts had intact TGFβ signaling, we performed 
immunofluorescent staining of phosphorylated-Smad2 (p-Smad2) upon TGFβ1 ligand 
treatment. Cells with intact TGFβ signaling should have increased nuclear p-Smad2 after 
TGFβ1 ligand treatment. WT fibroblasts but not Col1a2.ΔβRII fibroblasts had increased 
nuclear staining of p-Smad2 with TGFβ1 ligand treatment, confirming that the mutant 
fibroblasts do not have functional TGFβ signaling (Figure 4.3). Immunofluorescent 
staining also revealed that all cultures (WT and Col1a2.ΔβRII show positive staining for 








Figure 4.3  Primary Culture of WT But Not Col1a2.ΔβRII Fibroblasts Had 
Increased Nuclear p-Smad2 Staining After TGFβ1 Ligand Treatment. 
WT or Col1a2.ΔβRII Fibroblasts (10,000 cells/well) were plated in a chamber slide 
for 24 hours before treatment with either TGFβ1 ligand (2.5nM) or vehicle for 2 hours 
before being fixed and stained for  p-Smad2 and vimentin. All fibroblasts stained positive 
for the fibroblast marker, vimentin (red). After a 2 hour treatment with 2.5nM TGFβ1 











FSP.ΔβRII but Not Col1a2.ΔβRII Fibroblasts Enhanced Migration and Invasion of 
HNSCC Cell Lines  
 
Since little is known about the contribution of different subpopulations of 
fibroblasts to tumor progression, we used the two fibroblast models, FSP.ΔβRII and 
Col1a2.ΔβRII in conjunction with known HNSCC cell lines, FaDu, Cal27, and MSK921, 
to determine if the fibroblast subpopulations differentially regulated tumor properties. 
FaDu and Cal27 both have disrupted TGFβsignaling, while this pathway remains intact in 
MSK921 cells. A Boyden chamber assay was modified to have fibroblasts plated in the 
lower chamber, which were given 48hrs to condition the media that would act as a 
chemoattractant. HNSCC tumor cells were added to the upper chamber and allowed to 
migrate or invade through matrigel. Based on this study, we found that FSP.ΔβRII 
conditioned media enhanced the invasion of MSK921 tumor cells while Col1a2.ΔβRII 
conditioned media decreased both the migration and invasion of FaDu and the migration 
of MSK921 HNSCC cells (Figure 4.4). Additionally, we found that while the presence of 
any fibroblasts increased the number of colonies HNSCC cells were able to form in soft 
agar, Col1a2.ΔβRII fibroblasts co-cultured with HNSCC cells did not enhance colony 
growth in a soft agar assay, or alter the cell cycle of HNSCC as compared to WT 
fibroblasts (Figure 4.5). These data demonstrate how subpopulations of fibroblast have a 
differential influence on HNSCC tumor cells that may be dependent, in part, on intact 







Figure 4.4  FSP.ΔβRII but not Col1a2.ΔβRII Fibroblasts Increased Invasion of 
HNSCC with Intact TGFβ Signaling. 
(A, B) Boyden chamber assay of migration and invasion. WT, FSP.ΔβRII, or 
Col1a2.ΔβRII fibroblasts were plated in lower chamber, and allowed to condition the 
media as a chemoattractant. (A) FaDu or (B) MSK921 cells were added to the upper 
chamber and allowed to migrate/invade. Migration and invasion was normalized to the 







Figure 4.5  WT and Col1a2.ΔβRII Fibroblasts Equally Increased HNSCC Colony 
Growth in Soft Agar, but Showed No Difference in Altering HNSCC Cell Cycle. 
(A, B) Soft agar assays of HNSCC co-cultured with WT, Col1a2.ΔβRII, or a 50/50 
mixture of both. (A) FaDu and Cal27 HNSCC that do not have intact TGFβ signaling and 
(B) MSK921 HNSCC that do have patent TGFβ signaling. (A) Shows representative 
wells from a FaDu assay. (C, D) Cell cycle analysis with WT or Col1a2.ΔβRII fibroblasts 
plated under a 0.4µm insert containing HNSCC tumor cells. (C) FaDu and (D) Cal27. 








Figure 4.6  Conditioned Media from Col1a2.ΔβRII Fibroblasts Did Not Alter E-
cadherin. 
Cultured FaDu cells were exposed to conditioned media from WT or Col1a2.ΔβRII 












 To determine if deletion of TGFβ in fibroblasts can influence EMT properties of 
tumor cells, conditioned media was added to FaDu cells and EMT regulator E-cadherin 
was examined. Immunofluorescent staining showed no significant change in the 
localization or intensity of E-cadherin staining (Figure 4.6).  
 
Co-transplant of HNSCC Cell Lines with ΔβRII Fibroblasts Did Not Enhance 
Tumor Growth or Metastasis  
 
Recent studies have found that fibroblasts can play an important role in metastasis 
[239]. To investigate if the trend of altered invasion correlated with metastasis in vivo, we 
co-injected HNSCC cell with WT, FSP.ΔβRII or Col1a2.ΔβRII orthotopically into 
athymic nude mice. There was no difference in tumor growth or metastasis to local 
cervical lymph nodes in two separate cell lines (Figure 4.7, Table 4.1). 
 To further determine if the Col1a2.ΔβRII fibroblasts had an influence on tumor 
properties, we used immunofluorescent staining of the above mentioned tumors to 
examine angiogenesis, TGFβ signaling activation, and cellular proliferation. To assess 
angiogenesis, tumors were stained with CD31. Quantification of the staining revealed no  
difference between Cal27 or FaDu cells injected alone, with WT fibroblasts, or with 
Col1a2.ΔβRII fibroblasts (Figure 4.8A-D). As previous work done with the FSP.ΔβRII 
fibroblasts showed increased TGFβ1 ligand secretion by these fibroblasts [190], we 
wanted to assess if the tumors co-injected with Col1a2.ΔβRII fibroblasts had increased 
TGFβ signaling activation. Immunofluorescent imaging of p-Smad2 showed no change 








Figure 4.7  Col1a2.ΔβRII Fibroblasts Did Not Alter Tumor Growth or Histology of 
HNSCC Cell Lines. 
(A, B) Orthotopic co-injection of HNSCC cell lines with WT, Col1a2.ΔβRII, or a 
50/50 mixture of WT/Col1a2.ΔβRII fibroblasts (5x105 cells). (A) FaDu (1.5x105 
cells/injection) (B) Cal27 (1.0x10
5
 cells/injection) (C) H&E staining of representative 









Table 4.1  Col1a2.ΔβRII Fibroblasts Did Not Increase Metastasis in HNSCC. 
Orthotopic co-injection of FaDu (1.5x10
5
 cells/injection) or Cal27 (1.0x10
5
 
cells/injection) with WT, Col1a2.ΔβRII, or a 50/50 mix of WT/Col1a2.ΔβRII fibroblasts 
(5x10
5
 cells per injection). Cervical lymph nodes (CLN) were harvested from these mice 
during necropsy and metastases were determined by H&E histology. Mice with one or 
more positive lymph nodes were counted. 
 
Cells Injected 
# Mice with CLN 
Metastasis 




   
        FaDu Only 7 14 50.0 
        WT 9 20 45.0. 
        Col1a2ΔβRII 5 12 45.5 
        50/50 
WT/Col1a2.ΔβRII 
5 10 50.0 
Cal27    
        Cal27 Only 0 9 0.0 
        WT 1 10 10.0 
        Col1a2.ΔβRII 2 14 14.3 
 
 
fibroblasts (Figure 4.8A, B, E, F). Proliferation of tumor cells was assessed by injecting 
live mice with BrDu, then using immunofluorescent staining to detect the incorporated 
BrDu. This experiment showed that in the Cal27 tumors, Cal27 cells co-injected with 
WTfibroblasts had decreased BrDu staining relative to both tumors injected alone or co-
injected with Col1a2.ΔβRII fibroblasts, indicating decreased proliferation (Figure 4.8A, 
G). However, based on the tumor growth curves (Figure 4.7B), all of these tumors grew 
at the same rate. Additionally, FaDu tumors showed no difference in BrDu staining 
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Figure 4.8 Tumors From Co-Injected HNSCC Cells and Col1a2.ΔβRII Fibroblasts 
Did Not Have Altered Angiogenesis, Smad Activation, or Proliferation. 
(A, B) Quantification of CD31, p-Smad2, and BrDu staining of (A) Cal27 and (B) 
FaDu orthotopic co-injection tumors. Tumor cell co-injected with either WT or 
Col1a2.ΔβRII fibroblasts (150,000 tumor cells/500,000 fibroblasts per injection). (C-H) 
Immunohistochemistry of orthotopic tumors from co-injection of Cal27 and FaDu tumor 
cells with WT or Col1a2.ΔβRII fibroblasts. (C) Cal27 and (D) FaDu tumors stained with 
CD31 and K14 as a counter stain. (E) Cal27 and (F) FaDu tumors stained with p-Smad2 
and vimentin as a counter stain. (G) Cal27 and (H) FaDu mice were injected with BrDu 2 
hours before being euthanized. Fixed tumor samples were stained for BrDu and K14 as a 













Col1a2.ΔRII Mice Did Not Have Altered Susceptibility to Chemically-Induced 
Carcinogenesis  
 
 As primary culture of cells can inherently alter the properties of those cells, and 
all of the experiments thus far discussed have been performed with primary cultured 
fibroblasts cells, we wanted to move to an entirely in vivo model using chemically-
induced carcinogenesis. The chemical 4-Nitroquinoline 1-oxide (4NQO) is a DNA 
adduct-forming carcinogen that has been shown to mimic the mutations seen in human 
HNSCC caused by excessive tobacco and alcohol use [240]. We treated TGFβRIIf/f 
(TGFβRII) and Col1a2.TGFβRIIf/f mice with Tamoxifen to induce deletion of TGFβRII. 
We then treated the TGFβRII and Col1a2.ΔβRII mice with 4NQO for sixteen weeks. 
Starting at 14 weeks, mice were assessed every other week for oral tumor formation and 
weight loss. The endpoint used for this study was greater than 20 percent weight loss. 
There was no difference in the rate of visible oral lesions between the TGFβRII and 
Col1a2.ΔβRII mice. Additionally, there was no difference in the number of visible 
lesions on the tongue, esophagus, forestomach, pallet, or buccal tissues upon necropsy of 
TGFβRII and Col1a2.ΔβRII mice (Table 4.2). Furthermore, analysis of survival using a 
Kaplan-Meier curve showed no difference in the mortality rate between TGFβRII and 
Col1a2.ΔβRII mice (Figure 4.9). These data show that deletion of TGFβRII in Col1a2 






Table 4.2  Col1a2.ΔβRII Mice Did Not Have Altered Susceptibility To Chemically-
Induced Carcinogenesis. 
Visible tumors at time of necropsy in TGFβRII and Col1a2.ΔβRII mice that were 
exposed to the carcinogen 4NQO for 16 weeks in drinking water showed no difference in 
tumor formation. 
 








# Mice 15/17 12/13 
% 88.24 92.31 
Esophagus 
# Mice 15/17 11/13 
% 88.24 84.62 
Forestomach 
# Mice 5/17 4/13 
% 29.41 30.77 
Pallet 
# Mice 4/17 3/13 
% 23.53 23.08 
Buccal 
# Mice 3/17 2/13 
% 17.65 15.38 
 
 
FSP.ΔβRII but Not Col1a2.ΔβRII Fibroblasts Had Increased HGF and TGFα  
 
 Based on a previous study by Cheng et al, FSP.ΔβRII fibroblasts have increased 
expression of HGF, TGFα, and MSP that contribute to mammary tumor growth and 
invasion [241]. To investigate if there were altered signaling pathways in Col1a2.ΔβRII,  
we did a microarray analysis comparing TGFβRIIf/f to Col1a2.ΔβRII fibroblasts (Figure 
4.10). We found that while there were many genes differentially regulated by these two 
sets of cells; however, there were not clear changes in pathways that are presently known 
to be involved in microenvironmental contributions to tumor progression. Two genes that 
have been shown to be involved in tumor progression, fibroblast growth factor 10 
(FGF10) and Spondin2 (SPON2) [242, 243], were up regulated (+6.04 and +13.77 
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respectively). QRT-PCR analysis confirmed that these genes were up regulated with 
FGF10 showing an approximate 250 fold increase and SPON2 having a 10-20 fold 
increase (Figure 4.10 D, E). Furthermore, Col1a2.ΔβRII fibroblasts did not have 
significantly different HGF or TGFα in the microarray data set (1.30 and 1.06 fold 








Figure 4.9  Col1a2.ΔβRII Mice Did Not Have Altered Mortality in Response to 
Chemically-Induced Carcinogenesis. 
Kaplan-Meir analysis of TGFβRII and Col1a2.ΔβRII mice that were exposed to the 
carcinogen 4NQO for 16 weeks in drinking water showed no difference in mortality. 
RII
f/f





Figure 4.10  Col1a2.ΔβRII Fibroblasts Had Different Gene Expression Pattern 
From TGFβRIIf/f Fibroblasts. 
(A-C) Microarray data comparing gene expression between TGFβRIIf/f and 
Col1a2.ΔβRII fibroblasts. (A) Growth factors (B) Extracellular matrix proteins (C) 
Matrix metalloproteinases. (D, E) QRT-PCR confirmation of two factors that are up 
regulated in Col1a2.ΔβRII fibroblasts. Factors were confirmed in two independently 
isolated Col1a2.ΔβRII cell lines. (D) FGF10 is up regulated by 249.6 and 271.6 fold in 





Subpopulations of Fibroblasts May Differentially Contribute To Tumorigenesis  
 
 Based on previous work done by Harold Moses’ laboratory showing FSP.ΔβRII 
mice developed spontaneous forestomach SCC [190], we anticipated that the same 
mutation driven by the Col1a2 promoter would produce similar results. However, we did 
not see any spontaneous tumor formation in the Col1a2.ΔβRII mice. There are a few 
explanations for the differences seen in these mouse models. As Col1a2 and FSP likely 
target different subpopulations of fibroblasts, it is possible that unique populations of 
fibroblast secrete altered growth factors, chemokines, and signaling molecules that 
differentially regulate tumor initiation. In fact, the role of FSP1 fibroblasts in skin 
tumorigenesis has been illustrated in a previous study done by Zhang et al. In that study, 
they found that FSP1 positive fibroblasts contributed to maintaining chronic 
inflammation by recruitment of inflammatory cells through a MCP-1 mediated 
mechanism [244]. It is possible that FSP1, but not Col1a2 fibroblasts, are a key 
component to chronic inflammation, which has been linked to tumorigenesis. Beyond the 
mentioned study, little research has been done in this area. 
Another possible explanation for the discrepancy between models is a difference 
in the specificity of the promoters. In fact, FSP1, also known as S100A4, can be up 
regulated and is a prognostic marker in several cancers including bladder, pancreatic, and 
breast cancers [245-250]. Additionally, S100A4 can be expressed by cells other than 
fibroblasts, mainly monocytes [251], while Col1a2 is only expressed by a subpopulation 
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of fibroblasts. It is possible that this difference in specificity may have contributed to the 
conflicting results seen in the transgenic animals; however, it would not account for any 
of the differences seen in the in vitro studies.  
 
Intact TGFβ Signaling in Tumor Cells May Be Necessary for Invasion Mediated by 
FSP.TGFβRII -/- Fibroblasts  
 
The in vitro studies showed that the FSP.ΔβRII fibroblasts were able to enhance 
the invasion of MSK921 but not FaDu HNSCC tumor cells. MSK921 tumor cells have 
normal Smad4 expression, and an intact TGFβ signaling pathway, where FaDu tumors do 
not. This might also account for why there was no difference in tumor growth or 
metastasis seen in the in vivo co-injection studies in the athymic nude mice. Only FaDu 
and Cal27, both HNSCC cell lines with absent Smad4 signaling, were used for the in vivo 
mouse studies. Additional studies are needed to clarify the necessity of TGFβ signaling in 
the tumor response to FSP.ΔβRII fibroblasts.  
 
FSP.TGFβRII -/- and Col1a2.TGFβRII -/- Fibroblasts Secreted Different Growth 
Factors  
 
Based on the work in this study and work done by Harold Moses’ laboratory, 
preliminary data suggests that FSP.ΔβRII and Col1a2.ΔβRII fibroblasts secrete different 
factors. Cheng et al found that mammary FSP.ΔβRII fibroblasts promote invasion 
through secretion of HGF, TGFα, and MSP in addition to TGFβ1 over secretion [241]. 
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However, based on microarray data in this study, buccal Col1a2.ΔβRII fibroblasts do not 
overexpress HGF, TGFα, or TGFβ1. There are some limitations to this comparison. 
Mainly, the fibroblasts in these studies were from different locations – mammary and 
buccal. It is likely that fibroblasts from different locals have altered gene expression. 
Additionally, a side-by-side comparison in which conditions were the same would be 
essential. 
 
Col1a2.ΔβRII Mice Did Not Have Altered Carcinogenesis  
 
To eliminate the variables associated with cultured cells, we turned to an 
immunocompetent in vivo mouse model of chemical carcinogenesis. Col1a2.ΔβRII mice 
did not have altered susceptibility or mortality associated with chemical carcinogenesis. 
This is not surprising given the rest of the data collected in this chapter; however, it 
provides further evidence that there is a clear difference in the population of cells 
activated by the FSP promoter as compared to the Col1a2 promoter. Further analysis of 
the tumor histology is pending, and may be important to discern if there are any 
morphological changes associated with Col1a2.ΔβRII derived tumors.  
In summary, we provide evidence that subpopulations of fibroblasts can 
differentially contribute to tumorigenesis and invasion. Furthermore, TGFβ signaling in 
HNSCC tumor cells is necessary for the invasive response to FSP.TGFβ-/- fibroblasts. 
Finally, this study also presents preliminary data that there are different growth factors 




Recommended Future Experiments for This Project 
 
There are several key experiments that should be done to further the work of this 
project. First, it would be interesting to look at the lineage of the FSP1 as compared to 
Col1a2 fibroblasts to see if these represent unique fibroblasts niches. Another important 
experiment would be to compare Col1a2.ΔβRII and FSP.ΔβRII in the same chemical 
carcinogenesis model. It is possible that this might help discriminate the role of these 
unique fibroblast populations. 
Additionally, future studies should look at the role of an intact TGFβ signaling 
pathway in the tumor cells associated with TGFβRII loss fibroblasts. One experiment 
could examine how a cell line with patent TGFβ signaling, like MSK921, grows and 
metastasizes when co-injected with WT, Col1a2.ΔβRII, or FSP.ΔβRII in athymic nude 
mice. Other studies using TGFβ inhibitors would help unravel the importance of the 
TGFβ pathway in the tumor-stroma crosstalk.  
In addition to direct tumor studies, it would also be interesting to do a microarray 
comparing the buccal Col1a2.ΔβRII to the FSP.ΔβRII fibroblasts directly to determine 
what pathways are differentially regulated in these fibroblast subpopulations. Verification 
of the growth factors described in this study as well as ones identified in such a 
microarray could help clarify the role of subpopulations fibroblasts in the tumor 
microenvironment, potentially opening up new avenue for therapeutic intervention. 






SIGNIFICANCE OF WORK TO THE FIELD AND ADDITIONAL STUDIES TO 
ADVANCE THESE PROJECTS 
 
MiR-9 Projects (Chapters II and III) 
 
Inconsistencies between Mouse SCCS and Human HNSCC Models: Potential 
Influence of MiR-Related Machinery and Different Protein Isoforms 
 
There were several major inconsistencies between the two models examining the 
role of miR-9 in tumor progression. See Table 3.3 for a summary of miR-9 in these two 
models. There are several explanations that might explain the differences seen, and it 
would be important to reconcile the inconsistencies in the data by determining the cause 
of the discrepancy. 
MiRs undergo processing by cellular complexes, and also need cellular machinery 
to degrade the target messenger RNA. The differences seen between the mouse SCCS 
and human HNSCC could represent variation in the availability of miR-related cellular 
proteins. To investigate this possibility, an additional control experiment could be done. 
A miR with a known, predictable effect could be transfected into the cell lines used by 
both of these studies, and the predictable outcome compared between cell lines. For 
example, a vector containing luciferase and a miR targeting the luciferase mRNA could 
be used to assess for the relative amounts of available miR machinery.  
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Additionally, expression levels of key miR-related proteins, such as those 
involved in the RISC complex, Dicer, or Drosha could be measure and compared 
between experimental models; however, this would only give data on the expression 
level, not the relative availability of the processing machinery. It would not take into 
account competition of miR-9 with other miRs present in the tumor cells.  
It is possible that the relative availability of miR-related proteins would be the 
same in both the mouse and human models. Another possible explanation for the 
difference seen is species-specific mechanisms. We already suspect that there is a 
difference in the ABC transporters expressed by the human as compared to the mouse 
tumor cells based on the inability of verapamil to block the human tumor cell SP, but a 
different inhibitor, reserpine, was able to block the SP (Figure 3.5). These drugs both 
have additional targets. In addition to inhibiting the ABC transporters, verapamil targets 
L-type calcium channels and reserpine targets vesicular monoamine transporter. It is 
possible that the difference in effect is due to the off-target effect of these drugs; 
however, given that these drugs have been used for many years as a control for SP 
sorting, it is unlikely that it would explain the differences seen. A more likely explanation 
is that there are differences in the ABC transporter isoforms expressed in the human 
tumors. One way to investigate this would be to do a small, customized expression array 
for the isoforms of ABC transporters, and compare relative expression of ABC isoforms 
between mouse and human data. Differential ABC transporter expression might begin to 
explain the difference in the SP data; however, it would not explain all of the difference 
seen between these models. 
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Another explanation for the differences seen in the models is the role of the tumor 
microenvironment. We compared skin tumors to head and neck tumors. While these were 
both squamous cell carcinomas, there are differences in the environment in which these 
tumors grow, and it is possible that miR-9 mechanism rely on appropriate feedback from 
the surrounding stroma in order to promote metastasis and SP+ cell expansion. There are 
several experiments that could be done to investigate this possibility. First, the highly 
metastatic mouse SCCS, the B931-GFP and the B931-zip-9, could be injected 
orthotopically into athymic nude mice to determine if the ability of these tumors to 
metastasize is significantly altered by the tumor environment in which the tumor is 





 mouse tumors. These tumors would have the similar genetic 
profiles, and could be compared directly to the SCCS used in this study to determine if 
miR-9 levels influence metastasis and the SP+ cell population. Clarifying the importance 
of the tumor microenvironment in the context of these highly metastatic tumors would 
provide insight into the importance of miR-9 in tumor-stromal cross talk. 
 
MiR-9 Regulation of Metastasis: Do Dose Dependence, Collective Cell Migration, or 
Additional Mutations Play a Role? 
 
A dramatic increase in lung metastasis was seen in one of the mouse lines; 
however, similar results were not obtained in a second cell line or in the human model. 
One question that should be address is the fact that this phenomenon was only observed 







 tumors metastasized, had large SP+ cell populations, and high 
miR-9 levels, this data is correlative. Causally, only a single cell line, B931-GFP as 
compared to B931-Zip-9, was able to show a difference in lung metastasis based on miR-
9 levels (Figure 2.2). While this data was impressive, the B911-GFP compared to B911-
miR-9 lines did not show similar results. There was actually a trend towards decreased 
metastasis in B911-miR-9 tumor bearing mice (Figure 2.5). A likely explanation for this 
is that miR-9 levels need to be within an optimal range in order to increase the metastatic 
potential of the tumor cells. It would be important to repeat the experiment comparing 
high to low miR-9 expressing cell lines with similar miR-9 expression levels as the B931 
cell line. Several clones with differing miR-9 levels could be made to further clarify the 
impact of low, moderate, and high miR-9 levels.  
Higher miR-9 levels in the mouse model correlated with some EMT-like changes; 
however, there were some inconsistent findings worth discussing. High miR-9 tumor 
histology showed slightly more aggressive, SPCC morphology, but it was not dramatic. 
Additionally, knockdown of miR-9 was not sufficient to restore E-cadherin expression or 
decrease N-cadherin expression. It is possible that miR-9 may regulate metastasis through 
a different mechanism not involving EMT, such as collective cell migration. One study 
showed that N-cadherin regulated by decreased α-catenin is an important component to 
collective cell migration [75]. As we identified α-catenin as a miR-9 target, it is possible 
that it is influencing the cells in this manner. One way to determine if cells are collective 
migrating is to us a 3D migration assay. Furthermore, GFP expressing cells in a migration 
or invasion assay could undergo 3D live-cell imaging as another excellent way to 
visualize how the cells are moving- in an individual or collective fashion. 
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The human HNSCC data did not show any significant changes in the primary 
tumor morphology or staining; however, there were significant differences in α-catenin 
loss and increased MDR1 staining in lymph node metastasis in both the model and in 
human samples. These data suggest that miR-9 is not sufficient to cause loss of α-catenin 
or increase in the SP+ CSC population. It is important to note that the mouse cell lines 
used in Chapter II were derived from tumors that were serially passaged into athymic 
nude mice, presumably a process that increases the aggressiveness of the surviving tumor 
cells. Based on these data, it is likely that miR-9 alone is not sufficient but may be 
necessary to increase metastasis and SP+ CSC populations; additional, synergistic 
mutations are necessary. If this is true, it may be difficult to identify the key mutations 
involved in regulating miR-9 metastasis.  
These factors may be proteins, but other miRs could play a role as well. We 
actually have data examining both- Table 2.1 contains RNA-sequencing data from the 
mouse cell lines and tumors used in the studies presented in this work. However, this 
might not be the ideal comparison. This data compares the GFP to either the zip-9 or 
miR-9 expressing line, while both are from the same parental tumor that metastasized and 
had higher miR-9 levels than benign papillomas. Perhaps a better comparison would be a 
non-metastasizing low miR-9 expressing control to a metastatic higher miR-9 tumor. 
Even though this data may not be the ideal data set, there are many differential regulated 
proteins that might play a critical role in facilitating metastasis. The data needs to be 
confirmed by QRT-PCR and Western blotting before additional experiments should be 
undertaken. There are numerous interesting proteins that were differentially regulated in 
128 
 
the RNA-sequencing data, and further investigation may shed light on mechanisms 
driving metastasis as well as uncover new potential therapeutic targets. 
 
Potential Contribution of Alternative CSC Populations 
 
The Hoechst dye excluding SP was used in this study as a function marker for 
CSCs. However, CSCs are a diverse, heterogeneous population and additional CSC 
populations may be involved in the mechanisms described. There is one particular piece 
of data that does not fit with idea that SP+ cells correlate with increased metastasis. In 
Figure 2.5, B911-miR-9 tumor cells have very large SP+ cell populations, yet these 
tumors had decreased metastasis. One possible explanation is that the growth inhibitor 
signal from the high miR-9 levels was too strong for the CSCs to overcome in order to 
metastasize. Another explanation is that while there were many cells that gained the 
ability to efflux the Hoechst dye, these cells only gained that function but were not true 
CSC. It is important to clarify if the miR-9 mediated expansion represents a true 
expansion of CSCs, or if it only represents an increase in the cell population that has the 
function of effluxing Hoechst dye. It is possible that a subset of cells with additional 
properties and markers exist within this large SP+ population. A good way to resolve this 
question is to sort tumors for the SP+ population in B911-miR-9 and B911-GFP tumor, 
and inject small numbers of tumor cells into the flanks of nude mice to determine if these 
cells are able to initiate tumors in very small numbers. Alternatively, the sorted tumors 
could be used in a sphere forming assay to quantify the CSC properties of the SP+ cell 
population. Finally, it would be interesting to sort these tumors for additional CSC 
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markers, such as CD24+/CD44+, to determine if miR-9 expands multiple CSC 
populations, or only the one represented in the SP+ sorting. The answers to these 
questions would help shed light on the role of heterogeneous CSC populations in tumors.  
 
Depolyploidization in Metastasis 
 
In the course of this study, we came across an important biological phenomenon 
that is likely unrelated to miR-9; however, I think it is an important discovery that 
warrants further investigation. In Chapter II, I found that the B931 tumor cells were 
predominantly tetraploid, yet the lung metastases sorted from these very tumors were 
diploid or pseudo-diploid (Figure 2.6). There are several potential explanations for this 
data. The first explanation is that a subpopulation of the tumor always remains diploid 
and only these cells are able to metastasize. While this is possible, it has clearly been 
shown that tumors in polyploidy states gain more mutations that allow them to be 
increasingly aggressive. This would not fit well with a diploid-only explanation. An 
alternative explanation is that polyploidy cells undergo multipolar mitosis, resulting in 
multiple daughter cells, of which one is potentially pseudo-diploid (reviewed in [215]). 
This process, known as depolyploidization, has received some attention in recent years in 
the cancer field; however little is known about the significance of this process. One study 
of a human colon carcinoma cell line showed that decreased p53 and increased MOS 
were important for multipolar mitosis [216]. Similarly, a study found that p53 and 
RhoA/ROCK expression decreased multipolar mitosis in tetraploid human and mouse 
cells [252]. Another study found that radiation-induced mitotic catastrophe in human 
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tumor cells caused formation of synaptonemal complexes normally only found in 
meiosis. This study also showed increased expression of several meiosis-mediating 
proteins including synaptonemal complex protein 3 (SYCP3), REC8, and DMC1 [253].  
Our mouse SCC tumor xenograft is an excellent model to study this process. It 
can be difficult to find models where metastasis are large enough and distinct enough to 
study in detail; however, our mice get aggressive, large lung metastasis that can be 
isolated for further study.  
To address the question of if tumor cells are undergoing depolyploidization, 
expression levels of some of the proteins mentioned above including MOS, 
RhoA/ROCK, SYCP3, REC8, and DMC1 should be assessed in both in vitro and in vivo 
cells. It is unknown how many cells undergo this process, and it may be difficult to detect 
in whole tumor RNA samples; therefore using immunofluorescent staining of tumor 
samples or laser capture microscopy might work better to isolate tumor from stroma.  
Perhaps a more interesting question is if the living daughter cells of the tumors 
that undergo depolyploidization are the tumor cells that are metastasizing to the lung. A 
good way to address this question if at least one of the meiosis-specific proteins from 
above is shown to be expressed in the primary tumor would be to transduce tumor cells 
with Cre with the promoter region for the meiosis-specific gene and an inducible 
luciferase construct with an upstream stop codon that would get deleted, similar to the β-
galactosidase system used in chapter IV. In this system, cells that induced 
depolyploidization would cause constitutive expression of GFP. The daughters of these 
cells should express luciferase, and could be tracked to see if the lung metastases are 
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from this particular pool of cell. Using luciferase would also allow time-dependent 
factors to be investigated as well.  
Another faster but not as definitive method to investigate this question would be 
to sort luciferase expressing tumor cells by tetraploid or diploid status, then inject them 
into the tail veins of mice to determine if they have differential rates of establishing lung 
metastasis. This experiment would help determine if there is a difference in extravasation 
and colonization between tetraploid and diploid tumor cells; however, it would not be 
able to answer the overall question of if the diploid cells arise from the tetraploid cell 
population. Little is known about the physical chromosomal state in the context of 
metastasis, and any information revealed would help fill a critical gap in understanding 
the importance of ploidy state during metastasis. 
 
Subpopulations of Fibroblasts Project (Chapter IV) 
 
Subpopulations of Fibroblasts Differentially Regulate Tumorigenesis  
 
It is widely accepted that fibroblasts represent a heterogeneous population of 
cells; however, little work has been done in the cancer field to clarify if within this 
heterogeneity exists specific groups of fibroblasts that differentially influence tumor 
progression. Based on the work done in this study, FSP1 and Col1a2 promoters represent 
two fibroblast populations that have differential effects on tumor initiation, invasion, and 
migration in the context of having TGFβRII deletion. Previous work done by Harold 
Moses’ laboratory showed FSP.ΔβRII mice develop spontaneous forestomach SCC 
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[190], and fibroblast isolated from these mice have the ability to increase tumor invasion 
through secretion of numerous factors including HGF, MSP, and TGFα [241]. Another 
study recently found that FSP.ΔβRII fibroblasts cause inflammatory-mediated genetic 
and epigenetic changes in the neighboring epithelium in the forestomach [254]. However, 
the Col1a2.ΔβRII mice made by our laboratory not only did not form spontaneous 
tumors, but they also did not have altered chemical carcinogenesis (Figure 4.9, Table 
4.2).  
It is likely that this difference represents the contribution of two subpopulations of 
fibroblasts to the tumor microenvironment, similar to how different populations of 
macrophages may play a specific role in tumor progression. To learn more about this 
dynamic, it would be important to determine if FSP1 and Col1a2 represent unique or 
overlapping fibroblast populations. One way and perhaps the best way to answer this 
question is through lineage mapping. An alternative to this is to address the question by 
isolating one population of fibroblasts, for example FSP1 fibroblast that express GFP, 
and then look for the expression of Col1a2 by QRT-PCR or the protein by Western blot. 
Whether these cells represent unique or overlapping fibroblast populations would help 
clarify the role they play in tumor progression.  
Additionally, the FSP1 and Col1a2 TGFβRII deleted fibroblasts secrete different 
factors into the tumor microenvironment. To help address the question of what is 
different between these two fibroblast populations, it would be important to do a 
microarray comparing these fibroblasts directly and perhaps more interestingly, without 
the TGFβRII mutation. Differentially regulated proteins would shed light on the role that 
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the two fibroblast populations may have in tumor progression, with or without additional 
mutations. 
 
FSP1: Is It a Reliable Marker for Fibroblasts? 
 
FSP1, or S100A4, is expressed in more than just fibroblasts. S100A4 is also 
expressed in monocytes [251]. Conversely, Col1a2 is specific for a subpopulation of 
fibroblasts. Furthermore, FSP1 is up regulated in certain cancers, and may serve as a 
prognostic marker in cancer [245-250]. It has also been up regulated in inflammation. 
This brings into question the possibility that the spontaneous forestomach tumors seen in 
this model may have been due to either immunologic abnormalities or activated FSP1 in 
the epithelia of regions with inflammation. Previous work done by our laboratory 
indicates that TGFβRII deletion in epithelial cells does not result in spontaneous tumor 
formation without additional mutations [255]. This suggests that even if FSP1 caused 
deletion of TGFβRII in the epithelial tissue, it would not have been sufficient to cause 
spontaneous forestomach tumors. It is still possible FSP1 expressing monocytes may 
have deleted TGFβRII and contributed to the formation of spontaneous tumors. In fact, 
one of the studies mentioned above found that inflammation was a key component in the 
FSP.ΔβRII mouse development of spontaneous forestomach tumors [254]. To investigate 
the potential contribution of ΔTGFβRII in monocytes, a mouse model using an inducible 
monocyte deletion of TGFβRII could be compared to the results seen in these studies. 
It is possible that this difference in specificity between the promoters may have 
contributed to the conflicting results seen in the transgenic animals; however, it would 
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not account for any of the differences seen in the in vitro studies, such as the difference in 




The overall work done in this thesis highlights the complexities regulating 
metastasis and tumor progression. While there were two distinct projects represented, the 
concepts of tumor-stromal crosstalk, the tumor microenvironment, tumor cell invasion, 
and EMT are important processes linking these distinct works to the bigger goal of the 




MATERIALS AND METHODS 
 
MiR-9 Projects (Chapters II and III) 
 
Generation of Tumors from Mouse Models  
 
All animal experiments were conducted using protocols approved by the IACUC 
at University of Colorado Denver Anschutz Medical Campus.  
Mice were bred to contain the following transgenes: a Keratin 15 promoter driven 
cre recombinase (K15.CrePR1, on a B6SJL background)[256], Smad4 with exon 8 
flanked by Lox P sites (Smad4
f/f





, on a C57BL/6J background) [258]. Activation 
of these mutant alleles was achieved by application of RU486 (100l of 0.2g/l in 70% 
ethanol) to shaved dorsal skin of 3-week old transgenic mice for 5 consecutive days. 
Presence of transgenes was confirmed and verification of transgene activation was 
performed as previously described [12]. 
Mice were examined at least once per week for tumor development and once 
tumors became visible mice were monitored daily. Tumor bearing mice were euthanized 
when tumors reached 2cm in diameter, or if the mice were moribund. Necropsy was 
performed on each euthanized mouse to identify primary tumors and metastasis. Tumor 




Tumor Histology  
 
Dissected tumors, local lymph nodes, and lungs were fixed in 10% neutral-
buffered formalin for 24 hours, embedded in paraffin, sectioned to 6m thickness and 
stained with Hematoxylin and Eosin (H&E). Tumors and metastasis were diagnosed and 






 Primary Cell Lines.  
 
Primary tumor cell cultures were generated as we previously described [259]. 
Briefly, tumor pieces were digested in collagenase II (Worthington) in Hank’s buffered 
saline for 30 minutes at 37C. After this time, the cells were manually dissociated by 
pipetting up and down approximately 10 times with a 10ml serological pipette. Cells 
were incubated at 37°C for an additional 15 minutes. Cells were filtered through a 70µm 
filter and washed in DMEM (Invitrogen) with 10% FBS. Cells were plated in 10cm 
culture dishes in DMEM with 10% FBS with1x antibiotic-antifungal (Invitrogen) and 
cultured at 5% CO2 in a standard cell culture incubator. Prior to subculturing, cells were 
washed with D-PBS (Invitrogen), treated with TrypLESelect (Life Technologies) for 2 
min and floating cells discarded to select for epithelial cells. This selection was repeated 
prior to the subsequent 3-5 subcultures or as needed to remove fibroblast contamination. 
Future passaging was done by washing cells with D-PBS, treating cells with 
TripLESelect for 10 minutes, and centrifuged at 800RPM for 5 minutes to remove 
TripLESelect. Cells were plated in 10cm cell culture plates in DMEM with 10% FBS 
137 
 





Passaging was done by washing cells with D-PBS, treating cells with 
TripLESelect (Life Technologies) for 10 minutes, and centrifuged at 800RPM for 5 
minutes to remove TripLESelect. Cells were plated in 10cm cell culture plates in 
appropriate media. Tumor cell lines (B911, B931, FaDu, Cal27) were cultured in medium 
of DMEM (Invitrogen) with 10% FBS and 1x antibiotic-antifungal (Invitrogen). Tumor 
cell lines M3a2 and M4e were cultured in medium of 50/50 DMED/F12 (Invitrogen) with 
10% FBS and 1x antibiotic-antifungal. Cells were plated in 10cm culture dishes and 
cultured at 37⁰C with 5% CO2 in a standard cell culture incubator.  
 
Stable MiR-9 Overexpression and MiR-9 Knockdown Transduction   
 
For miR-9 overexpression, lentiviral vectors containing either a GFP labeled 
precursor miR-9-1 (miR-9) or a GFP control construct alone (miR-9 control) (System 
Biosciences) were transfected into 293T cells along with lentiviral packaging mix 
(System Biosciences) using Lipofectamine 2000 (Invitrogen).  For miR-9 knockdown, 
lentiviral vectors containing a GFP control construct and antisense miR-9 knockdown 
construct (Zip-9) that produces shRNA in a short single stranded anti-miRNA for miR-9, 
or a GFP control construct and a construct with an antisense GFP knockdown construct 
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that produces shRNA in a short single stranded anti-miRNA for GFP (Zip-9 control) 
(System Biosciences) were transfected into 293T cells along with lentiviral packaging 
mix (System Biosciences) using Lipofectamine 2000 (Invitrogen).  These constructs also 
have puromycin resistance. The virus containing media was harvested at 24, 32 and 48 
hours, and was overlaid on recipient cell lines for 24 hours. Recipient cell lines were 
expanded and flow sorted for GFP positivity to select for transduced cells, or selected 
using 2.5µg/ml puromycin. Cells were cultured as described above. 
 
Tumor Cell Injections  
 
For flank injections 5,000 tumor cells (B911/B931) were prepared by washing 
cells with D-PBS, treating cells with TripLESelect for 10 minutes, and centrifuging at 
800RPM for 5 minutes to remove TripLESelect. Cells were resuspended in EMEM 
media (Invitrogen) and live cells were counted using Trypan Blue. Tumor cells kept on 
ice were resuspended to a concentration of 5,000 cells/50µl with EMEM. Tumor cells (50 
µl) were injected subcutaneously into the flanks of 8 week old female athymic nude mice. 
Tumors were measured weekly with digital calipers, and mice were monitored for weight 
loss. 
For orthotopic injections, human head and neck SCC cells (FaDu 150,000 cells, 
Cal27 100,000 cells or M3a2/M4e 250,000 cells) were prepared as described as above. 
Cells were resuspended in EMEM to a concentration of the above mentioned cell number 
per 16µl. Cells kept on ice were mixed with matrigel (20%) and 20ul of cells in 
EMEM/matrigel were injected into the floor of the mouth as described [260]. Briefly, 
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mice were anesthetized using isoflurane and restrained. The tongue was displaced using 
gauze-covered forceps, and needle was inserted into the tissue under the tongue. Tumors 




For mouse chemotherapy, 5,000 tumor cells were subcutaneously injected into the 
flanks of 8 week old female athymic nude mice as described under “Tumor Cell 
Injections”. Once tumors had an average diameter between 5-10mm as measured with a 
digital calipers, mice were divided into treatment groups with similar average tumor 
sizes. Mice were given IP injections of vehicle or verapamil (25mg/kg) daily with a 
schedule of 5 days on, 2 days off. Vehicle or docetaxel (20mg/kg) was given by IP 
injection on days 3 and 10. Tumors were measured weekly with digital calipers. 
Verapamil (6.25mg/ml in normal saline) and docetaxel (2.5mg/ml in 10% tween 80, 5% 
Ethanol in PBS) were made immediately before use. 
 
Flow Cytometry  
 
Tumor cell suspension was prepared as described [261]. Briefly, tumors were 
harvested from mice, chopped into small pieces, and digested in collagenase II 
(Worthington) in Hank’s buffered saline solution (325 U/ml) at 37°C for 30 minutes. 
After this time, the cells were manually dissociation by pipetting up and down 
approximately 10 times with a 10ml serological pipette. Cells were incubated at 37°C for 
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an additional 15 minutes and filtered (70µm filter). Cells were washed with PBS with 3% 
FBS and HEPES buffer and centrifuged at 1000RMP for 5 minutes. Cells were counted, 
including live and dead cells, and resuspended in PBS with 3% FBS and HEPES buffer  
to a concentration of 1x10
6 
cells per 1ml. Cells were stained with 25ng/ml Hoechst 33342 
dye (Sigma-Aldrich) at a concentration of 1x10
6 
cells per 1ml in PBS 3% FBS with 
HEPES buffer for 90 minutes at 37°C as previously described [110, 262]. Control cells 
were stained in the presence of 100µM verapamil to inhibit Hoechst dye efflux. The cells 
were washed in PBS 3% FBS, resuspended in 1ml of PBS 3% FSB with HEPES, and 
stained with 1:50 FITC-CD31 (eBioscience) and 1:200 FITC-CD45 (eBioscience). When 
sorting tumor cells containing GFP positive cells, 1:50 APC-CD31 (eBioscience) and 
1:200 APC-CD45 (eBioscience) were substituted for the FITC-conjugated antibodies. 
The cells were washed, filtered (40µm filter) and propidium iodide (PI, Sigma-Aldrich) 





Paraffin slides of tumors fixed in formalin were prepared by baking overnight at 
65⁰C. Slides were sequentially washed for 5 minutes each in the following solutions: 
xylene, xylene, 95% ethanol, 70% ethanol, 50% ethanol. Slides were washed 3 times in 
PBS for 5 minutes each, and then transferred into 1x citric acid in a pressure cooker for 5 
minutes. After cooling slides for 20 minutes, slides were slowly transferred back into 
water by slowly washing out the water.  
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Immunohistochemical staining was performed as previously described [68]. 
Briefly, peroxidase activity was blocked using 3% hydrogen peroxide solution for 10 
minutes at room temperature. Slides were washed 3 times in PBS for 5 minutes then were 
treated with pepsin solution (Lab Vision) for 5 minutes, and washed 2 times with PBS. 
Slides were permeablized using 1x fixation/permeablization buffer (eBioscience) for 5 
minutes, and washed 2 minutes in PBS. Next, slides were blocked using 15% serum of 
secondary antibody host, or bovine serum albumin in background reducing buffer with 
0.1% triton for 60 minutes at room temperature. Slides were placed in primary antibody, 
Mdr1 antibody (1:400, Abcam), in background reducing buffer with 0.1% triton 
overnight at 4⁰C. Slides were washed 3 times in PBS, and then stained with secondary 
antibody in background reducing buffer with 0.1% triton for 60 minutes at room 
temperature, and washed 3 times with PBS. DAB (3, 3'-diaminobenzidine) and chromatin 
was added to slides until slides turned brown, and then slides were washed with water, 
counterstained with hemotoxylin, and mounted using fluoromount. 
Slides were prepared as described above.  Immunofluorescence staining was 
performed as previously described [68]. Briefly, peroxidase activity was blocked using 
3% hydrogen peroxide solution for 10 minutes at room temperature. Slides were washed 
3 times in PBS for 5 minutes then were blocked using 12% bovine serum albumin in 
background reducing buffer with 0.1% triton for 60 minutes at room temperature. Slides 
were placed in primary antibody in background reducing buffer with 0.1% triton 
overnight at 4⁰C. Slides were washed 3 times in PBS, and then stained with secondary 
antibody in background reducing buffer with 0.1% triton for 60 minutes at room 
temperature, washed 3 times with PBS, and mounted using fluoromount. Primary 
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antibodies included -catenin (1:200, Abcam), Keratin 14 (1:200, Fitzgerald), E-
Cadherin (1:200, eBioScience), N-Cadherin (1:200, Abcam), vimentin (1:200, Sigma), 
and Keratin 14 (1:200, Fitzgerald). Alexa Fluor 488-conjugated (green) or Alexa Fluor 
594-conjugated (red) secondary antibodies (Invitrogen) were used for visualization. 
 
Invasion Assays  
 
Trans-well Matrigel invasion chambers (BD Bioscience) were prepared according 
to manufacturer’s instructions. Briefly, chambers were allowed to warm to room 
temperature, and were hydrated using DMEM (Invitrogen) with no additives and 
incubated for 2 hours at 37⁰C in 5% CO2. Tumor cells were washed in D-PBS, treated 
with TripLESelect for 10 minutes, centrifuged at 800RPM for 5 minutes, and 
resuspended in DMEM serum-free media with 1x antibacterial-antifungal. Cells were 




 tumor cells per trans-well in serum 
free medium with antibiotic-antifungal. DMEM containing 10% FBS was used as a 
chemoattractant in the bottom well. The cells were incubated at 37C in a standard tissue 
culture incubator for 24-48 hours. Non-migratory cells were removed from the inside of 
the well and migratory cells were fixed in 4% paraformaldehyde, and stained with 0.05% 
crystal violet. Air-dried membranes were fixed to slides using Fluormount G. The 
number of cells migrated per microscopic field (10X) was counted and averaged over 9 





Gene Expression Analysis 
 
Total RNA was isolated using a Qiagen miRNEasy Kit. One-step qRT-PCR for 
gene expression was performed using 50ng of RNA per reaction with the One-Step 
Brilliant II QRT-PCR system (Stratagene, Santa Clara CA). Expression of mRNA was 
measured using TaqMan® Assays-on-demand
TM 
probes (Applied Biosystems, Carlsbad 
CA). All gene measurements were normalized to a Gapdh (mm99999915_g1) RNA 
probe. Each sample was run in triplicate using 50ng of RNA and the data was analyzed 
using a standard relative quantification (ΔΔCt) method. Reactions were run on a 
Stratagene MX3000P qRCR machine (Stratagene, Santa Clara CA). 
miR-9 expression analysis by qRT-PCR was conducted using a two-step method.  
First miRNA specific cDNA was prepared using 5ng of starting RNA, and miRNA 
specific RT primers (Applied Biosystems). The RT reaction was carried out using the 
High Capacity RT Kit from Applied Biosystems according to manufacturer’s 
instructions. Once miRNA specific cDNA was prepared, the qRT-PCR reaction was run 
using TaqMan miR-9 probes and TaqMan Universal Master Mix (Applied Biosystems). 
miR-9 expression was normalized to a mammalian U6 small RNA probe (Applied 
Biosystems). 
 
RNA Sequencing  
 
RNA was harvested from tumor samples frozen in RNAlater or cultured cell lines 
using Qiagen miRNEasy Kit. Tumor RNA samples were pooled so each sample 
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represented 2-3 tumors. RNA harvests from 3 passages of cell lines were pooled for each 
cell line sample. Quality of RNA was assessed using a bioanalyzer. RNA samples were 
run and analyzed using the Illumina HiSeq2000 Sequencing by the UC Genomics and 
Microarray Core. For mRNA profiling, we quantified transcript levels in fragments per 
kilobase of exon per million mapped reads. The FPKM reflects the molar concentration 
of a transcript in the starting sample by normalizing for gene length and for the total read 
number in the measurement. This allows for comparison of transcript levels both within 
and between experiments.  The computational pipeline consisting of the open-source 
Tuxedo Suite comprising Bowtie, TopHat, and Cufflinks are typically used for alignment 
and discovery of differential gene expression. Each read generated by each sample will 
be mapped to the mouse genome by Bowtie.  Subsequently, Tophat will analyze these 
mapped locations and assign them their gene/splice variant of origin. The third program 
of the series, Cufflinks, calculates the prevalence of transcripts from each known gene 
based on normalized read counts.  From this we can determine significant isoform 
expression using ANOVA in R. Thus we used a custom pipeline consisting of 
gSNAP/Cufflinks/R for RNAseq profiling.  Once a gene list was formed, we utilized 




For all qRT-PCR data, error bars are represented as the standard deviation 




Subpopulations of Fibroblasts (Chapter IV) 
 
Mouse Models  
 
All animal experiments were conducted using protocols approved by the IACUC 
at University of Colorado Denver Anschutz Medical Campus.  
Mice (C57BL/6 background) were bred to contain the following transgenes: a 
Collagen type 2a promoter driven cre recombinase (Col1a2.CreER), TGFβRII with exon 
2 flanked by Lox P sites (TGFβRII f/f) and Rosa26, a β-galactosidase reporter with an 
upstream stop codon flanked by Lox P sites. Activation of these mutant alleles was 
achieved by oral dosing of Tamoxifen (1mg/kg in sesame oil) to 3-week old transgenic 
mice for 3 consecutive days. Presence of transgenes was confirmed and verification of 
transgene activation was performed as previously described [12]. Additionally, transgene 
activation was confirmed by β-galactosidase staining (see below). 
Mice were examined at least once per week for tumor development and monitored 
for weight loss. Necropsy was performed on each euthanized mouse to identify the 
presence of any tumors or metastasis. Tumor tissue was collected for histology. 
 
β-galactosidase Staining  
 
Tissue samples were prepared as described above under “Histology.” Slides were 
prepared using xylene-free methods. For cell culture, 10,000 cells were plated into 8-
chamber slides. Cells were harvested after 48 hours, washed with PBS, fixed for 10 
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minutes with 4% paraformaldehyde at room temperature. Cells or slides were washed 3 
times for 5 min each in PBS. Cells were then incubated overnight at 37 degrees in xgal 
solution (make sure tissue completely covered). X-gal (5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside) solution (50mg/mg) (Promega) was diluted to a final concentration of 
1 mg/ml in in X-gal dilution solution consisting of the following: 5mM Potassium 
Ferricyanide Crystalline (Sigma), 5mM Potassium Ferrocyanide Trihydrate (Sigma), 
2mM magnesium chloride (Sigma) in PBS, aliquoted and stored in dark at -20⁰C. Cells or 
slides were placed in X-gal staining solution overnight at 37⁰C, washed 5 times with PBS 




Dissected tumors, cervical lymph nodes, and tongues were fixed in 10% neutral-
buffered formalin for 24 hours, embedded in paraffin, sectioned to 6m thickness and 
stained with Hematoxylin and Eosin (H&E). Tumors and metastasis were diagnosed and 
scored according to histology. 
 
 
Generation of Primary Fibroblast Cell Lines from Mouse Models  
 
Three-week old Col1a2.TGFβRIIf/f.Rosa26 mice treated with oral Tamoxifen 
(1mg/kg) for 3 consecutive days to cause recombination of the transgene. These mice 
were euthanized and tissue was harvested from buccal mucosa. The buccal tissue was 
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chopped into small pieces on the bottom of a tissue culture plate. A glass coverslip was 
placed over the tissue pieces to prevent them from floating and media was added (RPMI-
1640 media containing 20% FBS, 1mM sodium pyruvate, 2mM L-glutamine, 10mM 
HEPES, 5x Penicillin-Streptomycin, 1x non-essential amino acids, 5mM NaOH, 0.1% β-
mercaptoethanol and 1mM Tamoxifen). Cells were incubated at 37⁰C with 5% CO2 for 
approximately 2-4 weeks with regular media changes. Once fibroblast had grown 
outward from the tissue pieces, cells were lifted using TrypLESelect and maintained in 
the media described above for 4 passages, after which, Tamoxifen was removed. 
Presence of transgene and recombination was confirmed using PCR, QRT-PCR, and 
staining for β-galactosidase. 
We obtained a Tgfbr2
fspKO.GFP 
mouse (generous gift from Harold Moses’ 
laboratory) to generate buccal fibroblasts that utilize FSP to drive Cre expression and 
recombination of homozygous floxed TGFβRII (henceforth referred to as FSP.ΔβRII 




Cells were passaged and maintained as described above under “MiR-9 Projects: 
Cell Culture,” using the following media: RPMI-1640 media containing 20% FBS, 1mM 
sodium pyruvate, 2mM L-glutamine, 10mM HEPES, 5x Penicillin-Streptomycin, 1x non-







Immunofluorescence staining was performed as previously described [68] and as 
described above under “MiR-9 Projects: Immunostaining”.  Primary antibodies included 
p-Smad2 (1:400, Abcam), Vimentin (1:200, Sigma), E-cadherin (1:200, eBioscience), 
CD31 (1:200, Abcam), K14 (1:200, Fitzgerald), and BrDu. Alexa Fluor 488-conjugated 
(green) or Alexa Fluor 594-conjugated (red) secondary antibodies (Invitrogen) were used 
for visualization. DAPI was used to visualize nuclei. 
 
BrDu Administration  
 
Live mice were injected intraperitoneally with 50 mg/kg of 5-bromo-2-
deoxyuridine (BrDu) 2 hours before euthanasia. Samples were fixed in 10% neutral-
buffered formalin for 24 hours, embedded in paraffin, sectioned to 6m thickness and 




One One-step qRT-PCR was performed as described above under “MiR-9 
Projects: Gene Expression Analysis.” Detection was done using TGFβRII 





Migration/Invasion Assays  
 
Trans-well Matrigel invasion and control (migration) chambers (BD Bioscience) 
were prepared according to manufacturer’s instructions and as described in “MiR-9 
Projects” above with the noted changes. Fibroblasts were plated in the lower chamber at a 
density of 5.0x10
4
 cells per well. After cells adhered, the media was changed to 0.1% 
FBS in DMEM. Fibroblasts were allowed to condition the media for 48 hours as a 
chemoattractant before tumor cells were plated in the upper chamber. Tumor cells were 
plated at a density of 2.5x10
4
 tumor cells per trans-well in 0.1% FBS in DMEM medium. 
The cells were incubated at 37C in a standard tissue culture incubator for 40 hours. Air-
dried membranes were imaged and ImageJ was used to quantify the area covered by 
migrated or invaded cells. 
 
Co-injection of Tumor Cells and Fibroblasts  
 
For orthotopic xenograft, human head and neck SCC cells (FaDu- 150,000 or 
Cal27- 100,000 cells) and WT, Col1a2.ΔβRII or FSP.ΔβRII Fibroblasts (500,000 cells) 








Cell Cycle Analysis  
 
Fibroblasts were plated in 6-well plates. Media was changed after 24 hours, and 
fibroblasts were allowed to condition the media (DMEM with 0.1% FBS with antibiotic-
antifungal) for 48 hours. HNSCC cells were plated above fibroblasts in 0.4µm cell 
culture inserts (BD Bioscience, #353493). HNSCC cells exposed to fibroblast 
conditioned media for 24 hours were harvested and washed with PBS. The cells were 
pelleted by centrifugation and resuspended in 1ml Krishan Stain (described in [224]) at a 
concentration between 0.1-1x10
6
 cells/ml. Krishan stain consisted of the following: 0.224 
g NaCit.2H2O, 9.22 mg Propidium Iodide, 1.0 ml 1% NP40 in H2O, 2.0 ml 1mg/ml 
RNase (DNase free), q.s. to 200ml with H2O. The cells were vortexed to mix and 
incubated at 4⁰C overnight. Cell cycle analysis was performed with a FC500 flow 





RNA harvested from TGFβRIIf/f and Col1a2.ΔβRII was used for microarray 
analysis. Analysis was run using MouseRef-8 v2.0 expression bead chip (Illumina, #BD-
202-0202) and was done by the Mind Research Network, Albuquerque, NM. Data was 
analyzed by the Translational Bioinformatics and Cancer Systems Biology laboratory, 
Aurora, CO. Briefly, multiple probe sets representing the same gene were collapsed, 
using the maximum value to represent the gene. The remaining 25,698 genes were 
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normalized using quartile normalization and analyze for significance using Statistical 
Analysis of Microarrays (SAM). 
 
Soft Agar Assay  
 
Soft agar assays were performed in 6-well plates. Individual wells were coated 
with 1.5 ml of base media consisting of 2x DMEM media with 20% FBS mixed with 1% 
noble agar (BD, #214230) stock to yield a final concentration of 0.5% agar. Upper media, 
consisting of 2x DMEM media with 20% FBS mixed with 0.6% noble agar stock to yield 
a final concentration of 0.3% agar, was kept at 42⁰C in a water bath while cells were 
prepared. The HNSCC cells (2.5 x 10
4
) and fibroblasts (5x10
4
) were harvested with 
TrypLESelect, washed with PBS, resuspended and mixed in upper media. HNSCC cells 
(2.5 x 10
4
/well) and fibroblasts (5x10
4
/well) were plated in 1ml of upper media gently 
added over the solidified base media. Soft agar cultures were incubated for 21 days and 
fed with 2.0 ml of DMEM with 10% FBS twice weekly. The resulting colonies were 
treated with 200 μl Nitroblue reagent (1 mg/ml, Amresco, #0329) and incubated at 37°C 
overnight to develop a blue stain. Colonies were photographed with a digital camera and 
the acquired images were analyzed using the ImageJ software. Number and size of 







Chemically-Induced Carcinogenesis  
 
Mice (C57BL/6 background) were bred to contain the following transgenes: 
Col1a2.CreER.TGFβRII f/f or TGFβRII f/f. Activation of these mutant alleles was 
achieved by oral dosing of Tamoxifen (100µg/ml) to 3-week old transgenic mice for 3 
days. Mice were treated with 200μg/ml of 4-nitroquinoline-1-oxide (4NQO) in the 
drinking water for 16 weeks. Starting at 12 weeks, mice were monitored bi-weekly for 
the appearance of oral lesions and for weight loss. Mice were euthanized when they had 
lost 20% of their body weight. Necropsy was performed, noting the number and size of 
all lesions in the upper digestive tract including buccal, tongue pallet, esophagus, 
forestomach, and metastasis to local cervical lymph nodes. Samples were collected for 
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TGFβRII recombination TAAACAAGGTCCGGAGCCCA 
 AGAGTGAAGCCGTGGTAGGTGAGCTTG 
K15.CrePR1  CGGTCGATGCAACGAGTGAT  
 CCACCGTCAGTACGTGAGAT 
Smad4 Floxed  GGGCAGCGTAGCATATAAGA (P9)  
 GACCCAAACGTCACCTTCA (P10) 
LSL-KrasG12D  CCTTTACAAGCGCACGCAGACTGTAGA  
 AGCTAGCCACCATGGCTTGAGTAAGTCTGC 
Smad4 deletion  AAGAGCCACAGGTCAAGCAG (P8)  
 GACCCAAACGTCACCTTCA (P10) 
LSL-KrasG12D 
recombination  
GGGTAGGTGTTGGGATAGCTG  
 TCCGAATTCAGTGACTACAGATGTACAGAG 
 
 
 
 
